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ABSTRACT
ROBUST BIOSENSORS FOR HEALTHCARE APPLICATIONS: FROM HIGHCONTENT SCREENING TO POINT-OF-CARE TESTING
SEPTEMBER 2017
NGOC D. B. LE
B.S., SHORTER UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Vincent M. Rotello

Efficient detection of proteins, mammalian cells, microorganisms and other
biological systems in complex mixture is essential in disease diagnosis and
environmental health. Therefore, technological platforms that provide sensors of high
sensitivity, selectivity and stability are greatly desired. Recently, the ‘chemical-nose’
sensing approach has proved to be an effective strategy for profiling bio-relevant targets
in complex mixtures. Detecting analytes in complex mixture is a challenge that
conventional specificity-based sensors are still trying to solve due to the requirement of
prior knowledge of the analyte, which is unknown in many cases. This thesis focuses on
how to develop simple and robust chemical-nose sensors for complex mixtures using
supramolecular interactions between nanoparticles, fluorescent proteins, enzymes, and
fluorescent polymers. We have successfully developed effective sensors for many
healthcare applications including chemotherapeutic drug profiling, cancer diagnostics,
environmental toxicity and bacterial detection. Throughout this dissertation, there is an
emphasis on moving from high-content screening to point-of-care testing, especially in
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cancer diagnostics. Overall, the chemical-nose sensors provide a simple generic tool for
bio-relevant analyte profiling, avoiding additional processing steps prior to screening as
seen in traditional methods. More importantly, chemical-nose sensors hold great promise
for addressing the needs in personalized screening of disease states and environmental
toxicology.
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CHAPTER 1
INTRODUCTION

1.1.  Biosensor
Efficient detection of proteins, mammalian cells, microorganisms and other
biological systems in complex mixture is essential in disease diagnosis, forensic,
agricultural, and environmental toxicity. Early detection of diseases or identification of
harmful chemicals in the environment provide the prospect of better health and alarm
people to take appropriate actions in a timely manner. Therefore, technological platforms
that provide sensors of high sensitivity, selectivity and stability are in high demand.
Biosensors have two functional components: recognition elements and
transducers. Recognition elements are receptors used to recognize and bind to the target
analytes. This interaction between the analyte and the receptor is designed to produce an
effect that can be measured by a transducer. Receptors can be biological species, such as
antibodies, enzymes, proteins, nucleic acid, or synthetic elements such as small
molecules, nanoparticles, and polymers. To transduce the analyte-receptor binding event,
a number of techniques are available including 1) optical (absorption, luminescence,
fluorescence, and surface plasmon resonance), 2) electrochemical, and 3) mass-sensitive
measurements (surface acoustic wave and microbalance).
The efficiency of a biosensor is critically related to the outcome of each process
associating with each component, recognition and transducer, in term of the response
time, signal-to-noise (S/N) characteristics, sensitivity, and selectivity of the system. Thus,
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much attention in the field has been focusing on improving the recognition process as
well as designing new signal transduction mechanisms. With the advent of nanostructures
and new interface materials, the pursuit of new recognition and transduction processes is
made possible for the development of novel biosensors.

1.2.  Biosensor designs: Lock-and-key specificity versus chemical-nose selectivity
Biosensors can be broadly split into two types of sensing designs: highly specific
sensing (lock-and-key approach), and array-based selective sensing (chemical-nose
approach). The former is a sensor that in its strict definition would be completely specific
to a single analyte and not recognize any other targets. In this context, the receptor is the
lock and the analyte is the key. The notion leads to the concept of one key that is
complementary to one lock, thereby opening up only one lock, recognizing only one
target. This idea is approached by antibodies, lectins, aptamers and enzymes. As an
example for using an antibody in identifying and capturing a target analyte, Sha and
coworkers developed a sensor for cancer circulating cells (CTCs). This sensor was
fabricated by combining capturing capability of a magnetic bead and specific labeling of
surface enhanced Raman scattering (SERS) nanotags.1 This bead was conjugated with
anti-EpCAM antibody to capture SKBR3 cancer cells. These cells were then labeled for
SERS detection by gold nanoparticles (AuNPs) functionalized with anti-HER2 antibody
(human epidermal growth factor receptor-2) (Figure 1.1).2 In a similar study, SERS-based
systems were further employed for in vivo tumor targeting.3
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Figure 1.1. Schematic illustration of the immuno-complex formed by nanoplex biotags
and magnetic bead conjugates binding to the model tumor cell. Republished with
permission from ref. 1.

There are several advantages when using the lock-and-key approach such as the
absence of false positive results and an ultrasensitive detection.4 However, since specific
recognition-based sensors require pre-identification of the biomarkers, they face certain
limitations when the analytes are unknown and/or their structures are not fully
characterized. In that case, detecting unknown analytes using lock-and-key sensing
approach is impractical. In addition, even when the biomarker is known, the specific
sensing approach would not be an ideal test for systems that contain multiple analytes
with varied biomarker levels among cell populations. For example, cancer cells present
multiple biomarkers on the cell surface and these markers coexist in normal cells at
different levels, making the detection of a specific biomarker that is strictly associating
with only cancer status nearly impossible. These subtle changes in the biomarker levels
could be indicative of dramatic phenotypic differences. As an alternative, sensors using
3

selectivity-based modality do not require the knowledge of a specific biomarker. On the
contrary, selectivity-based approaches capture the responses from complex analytes to
generate a signature for each sample. In a typical array-based sensor, a set of recognition
elements interacts with a number of different analytes or classes of analytes, providing a
process reminiscent of mammalian olfaction.5 This mechanistic similarity is why arraybased sensors are often denoted as chemical ‘‘noses’’ or ‘‘tongues’’ (Figure 1.2).6

Figure 1.2. Electronic nose devices mimic the human olfactory system. Adapted from
ref. 6.

Chemical-nose sensing approach mimics the mammalian olfactory system to
recognize mixtures of analytes. Overall, there are about 1000 genes that encode olfactory
receptors, and each olfactory receptor has multiple sites for odorant binding with
different affinity levels. This characteristic is known as crossreactivity.7,8 A generated
unique signaling fingerprint for a specific odorant is then interpreted in the olfactory
cortex by matching the signal with previously established patterns of analytes. This
process makes it possible to distinguish between thousands of odorants using just much
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fewer numbers of olfactory receptors (Figure 1.2). The effort of mimicking the olfactory
system for analyte detection has led to the first model of an 'electronic nose', reported by
Persaud and Dodd in 1982.9 Their idea was to detect different volatile compounds by
mimicking the three different stages of the human olfactory system, including interacting
with the odorant, establishing the pattern of the odorant, and identifing what the odorant
is using biochemical sensors.
The advantage of chemical-nose sensor is that it can be trained to recognize
complex mixtures without the knowledge of what types of biomarkers the mixture
contains. Chemical-nose approach is useful when the disease lacks an ideal biomarker or
biomarkers are poorly characterized such as in cancer disease. This method has been used
to sense calcium and metal ions, pH levels, sugars as well as cholesterol levels in blood,
cocaine in urine, and toxins in water.10,11 Chemical nose sensors can also recognize a
wide range of volatile organic compounds,12 amino acids,13 proteins,14 carbohydrates,15
mammalian cells.16
One of the strengths of nose-based sensing is the versatility of the methodology.
This versatility provides a challenge: array-based sensors need to be retrained and
validated for each new analyte, and baseline profiles for known samples must be
carefully examined to maximize accuracy.17 Perhaps the greatest challenge of nose type
sensing is the fundamental difference between this method and other biomarker-based
strategies. Just like our sense of smell, sensing using olfaction mimics is inherently
hypothesis-free, a situation with which many researchers are not yet comfortable. In this
dissertation, we focus on the development of chemical-nose sensors for healthcare
applications.
5

1.3. Gold nanoparticles and fluorescent polymers as efficient receptors for chemicalnose sensor designs
Gold nanoparticles (AuNPs) possess several distinctive physical and chemical
attributes that make them promising synthetic scaffolds for creating novel biosensor
systems.18 First of all, the size of the NP core is tunable from 1 – 150 nm, an ideal size
for the interaction of AuNPs with bio-relevant analytes.19 The high surface area-tovolume ratio of AuNPs provides dense ligand loading, enhancing the interaction with
analytes.20 These particles typically have a hydrophobic core for stability. For biological
applications, oligo(ethylene glycol) (OEG) is added in the linker to enhance
biocompatibility and minimize non-specific adsorption of other materials. Lastly,
recognition receptors on the surface of AuNPs are used for the interactions with bioanalytes. A common structure of ligands on a AuNP for biomolecular interactions is
shown in Figure 1.3. Most importantly, AuNPs have excellent quenching ability for
fluorophores, an ideal feature for biosensor design.

Figure 1.3. Schematic of common surface ligands on AuNPs used for interactions with
biological systems. The multifunctional particle monolayers featuring a hydrophobic core
for stability, OEG layer for biocompatibility, and recognition elements on the surface for
interaction with biomolecules.
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The diverse ligand functionalities enabled by the ease of AuNP synthesis, along
with unique features of AuNPs as mentioned above provide a versatile scaffold for
constructing biosensor using chemical-nose approach. Our group has pioneered the use of
AuNPs for chemical-nose sensing systems by non-covalently assembling AuNPs with
different types of transducers such as fluorescent proteins (including EBFP2, EGFP, and
td Tomato) and conjugated fluorescent polymers. In this design, cationic AuNPs with
various functional headgroups form supramolecular complexes with anionic fluorescent
proteins or polymers (poly(p-phenyleneethynylene) (PPE) to quench their intrinsic
fluorescence. Competitive bindings of the bio-analytes release the fluorescent proteins or
polymers, resulting in their fluorescence recovery.21,22 This approach has been used
successfully for protein, cell, and tissue identification.
Another type of receptor that is suitable for the design of chemical-nose sensor is
fluorescent polymer. Besides the use of fluorescent polymer as transducers as described
previously, conjugated polymers can also act as receptor to recognize bio-analytes.
Unlike small molecules and nonconjugated polymers, these conjugated polymers are
more responsive to conformational or environmental changes due to its unity of
delocalized electronic structure of the polymer backbones. Such behavior of conjugated
polymers provides more dynamic interactions (either intra- or intermolecularly) that
could lead to various changes in the fluorescence outputs, providing a rich signature
profile for complex analytes, a requirement for chemical-nose approach. Conjugated
polymers can be designed to have high fluorescence quantum yields in aqueous solution
and ability to interact electrostatically with other charged species. These water-soluble
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polymers are also attractive because of their easily tailoring multivalent functionalities,
stability, and scalability properties. Some of the conjugated polymers that have been used
for chemical nose sensing are poly(p-phenyleneethynylen) (PPEs) and poly(paryleneethynylene)s (PAE) for the detection of proteins, antibiotics, explosives, and fruit
juices.23-26

1.4. High-content screening: ideal space for chemical-nose sensors
There is always high demand for rapid identification of mechanisms in drug
discovery and detections of serious diseases. Thus, high-throughput screening (HTS) and
high-content screening (HCS) have been extensively implemented to meet the demand.
While HTS focuses on rapid examination of the effects of thousands of testing
compounds in various in vitro and cell-based assays, HCS approaches might sacrifice
some of the high-throughput speed to achieve more information in phenotypic
complexity measured by the assay endpoints.
Whole cells have been the major target for many assays and have the potential to
provide rapid sensing with minimal processing, in contrast to approaches that need to
physically extract cell contents such as intracellular proteins, nucleic acids, or other
markers buried inside the cells. The rich environment presented by the cell exterior also
gives cell sensors the capability to read out the phenotypes of cells, a property that is the
final outcome of multiple factors including both genetic and epigenetic variations. Taking
advantage of the final phenotypic outcome of cells, HCS uses a set of analytical methods
such as automated microscopy, multi-parameter image processing, and visualization tools
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to extract data from different features of cell populations. These features include spatial
distribution of targets, individual cell and organelle morphology. For example, Young
and coworkers have developed a HCS method to profile mechanisms of action in drug
discovery that combines signals from multiple fluorescence probes that show cells’
features such as nuclear size, DNA replication, chromosome condensation, nuclear
morphology, and nuclear ellipticity. Some of these features have obvious biological
meaning such as the amount of DNA per nucleus. However, the biological importance of
other features has much less obvious meaning such as the DNA texture or nuclear
ellipticity. Biologists usually overlook these non-obvious features since they are not
‘hypothesis-driven’ markers, even though they may contribute some valuable insights.
The goal of HCS is to create a unique fingerprint of cell phenotypes composed of
multiple specific cell features using various fluorescence probes. These HCS approaches
are very powerful in profiling mechanism/cell status of interested. However, as we can
imagine, extracting numerous cell phenotypic features through staining, fixing and
imaging, these HCS methods face the limitation of multi-step processing of cells prior to
analyses. There are also challenges arising from limited dynamic range, time consuming
steps, and expensive instrumentation that restrict the applicability of these methods for
rapid screening.
As mentioned earlier, since chemical-nose sensor can create fingerprints for each
analyte including all obvious and non-obvious features of cells in a very rapid manner, it
presents an ideal method for minimizing number of cellular parameters typically found in
HCS assays to greatly expedite drug development and disease diagnosis.
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1.5. Chemical-nose sensors offer a new avenue for point-of-care testing
Changes in healthcare delivery trend have driven the widespread of point-of-care
testing (PoC) in disease diagnosis. This change is partly due to economic pressures and
the general recognition that cares need to be less fragmented and more patient-centered.27
The concept of PoC testing is aimed at delivering less costly care, closer to the patient’s
home and not around the provider. Typically, the testing process is quite disconnected
with the consultation process such that a patient has to deal with multiple doctor visits to
complete the health assessment. This issue appears clearly for those who have chronic
diseases such as diabetes where regular monitoring of glucose level by frequent blood
test is necessary. As a result, the growth in self-monitoring of blood glucose up to date is
the evidence for the need of more convenient and sometimes, more effective care.28,29

Table 1.1. The ASSURED guidelines that indicate the features that should be designed
into all POC testing devices. Adapted from ref. 28.

10

PoC testing can be divided into two categories: 1) small handheld devices and 2)
larger bench-top devices. The former type usually provides qualitative or semiquantitative determination of analyte concentrations. Some of the dominant technologies
are glucose biosensor strips or lateral flow strips using immobilized antibodies for
biomarker detections such as cardiac markers and infectious pathogens.29 The second
category includes larger devices to use in a laboratory setting but with reduced size and
complexity. These devices are used to monitor ‘critical care’ analytes such as blood
gases, electrolyte, and certain metabolites. Recently, molecular technique such as PCR
was incorporated into a sufficiently small device for infectious disease testing at the point
of care. The World Health Organization (WHO) determined desired features for PoC
devices as listed in Table 1.1, a guideline known as ASSURED.29 Of course, some
features might be more important than others, depending on the final end-users and
purposes (Figure 1.4). To further improve the concept of PoC testings to include the
parameters of end-users and test purposes that are lacking in the ASSURED guideline, a
recent PoC concept has been developed. This concept views PoC testing as multiple
components including 1) the complexity of technologies that ranges from simplest to
more sophisticated, 2) users including lay persons to highly trained workers, 3) settings in
which the test is needed including home, communities, clinics, peripheral laboratory, and
hospital. When we separate PoC need based on diverse settings, PoC tests do not need to
meet all the requirements listed in the ASSURED guideline. For example, malaria rapid
diagnostic tests used by community health workers in Africa or in-home pregnancy tests
need to be very simple, instrument-free and straightforward because the goal here is selfassessment. At the other end of the spectrum showed in Figure 1.4, hospitals have
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starting to implement more PoC testing programs. For example, emergency room doctors
use handheld ultrasound devices to rapidly diagnose and treat pregnancy complications.
Rapid tests are also being used in intensive care units to make timely decisions on patient
treatments. In this setting of health care delivery system, tests do not need to be
instrument-free or inexpensive. The users for these PoC tests are often well trained.

Figure 1.4. The spectrum of point-of-care testing. Adapted from ref. 30

The implementation of PoC devices will have tremendous healthcare and
economic benefits, especially in developing countries where easy access to health
providers is still limited. Looking through the lens of a global scale in both developing
and developed countries, PoC testing will reduce the cost of disease diagnosis, improve
survival and recovery rate of patients through more effective therapeutic treatments. This
trait is the direct result of early detection, a blessing provided by PoC’s ease of use.
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Despite much success in PoC testing, there are clearly areas where new PoC
technologies are lagging behind such as in cancer and infectious disease. The challenge
of developing PoC testing for these areas lies in the identification of an ideal biomarker.
For example, in cancer diagnosis, the search for the ideal biomarker that only associates
with the presence and the progress of cancer status is poorly characterized. There is a
wide baseline of biomarker in the population, even within the subpopulation of patients
that have the same type of cancer. This observation triggered the development of
personalized diagnostic devices for personalized medicine via patient-specific disease
profiling.
Chemical-nose sensors have great potential to advance personalized medicine.
The robustness of the system comes from the crossreactivity nature of nose sensors. They
can be trained and retrained for any analyte, any disease status, and any specific patient
with a simple design and no requirement of expensive and sophisticated instruments. In
2015, a perfect example of using the nose sensor for cancer diagnosis was reported in The
Guardian newspaper about a dog, named Frankie, who could detect thyroid cancer with
88 % accuracy among patients. Frankie was trained to lie down in front of patients’ urine
samples if he detected metastatic cancer.30
Researchers have been focusing on developing biomimetic devices that capable of
detecting cancer as seen in the dog, Frankie. Currently, the use of urine31 and breath32 as
samples in cancer diagnosis has been employed due to their attractive noninvasiveness.
When using urine samples as biofluids for analysis, one challenge is that the
concentrations of naturally occurring biomarkers are typically low. To compensate for
this limitation, an array of sensors with the ability to amplify biomarker concentration in
13

urine has been developed.33 For this purpose, a class of engineered mass-encoded
peptides with specific protease-sensitive moieties conjugated to iron oxide NPs were
synthesized. These synthetic biomarkers passively accumulate in the cancer tissue after
administration. Aberrantly active proteases in the tumor subsequently cleave the
protease-sensitive agents of these NPs, with the resulting fragments excreted in the
urine.34 Using a library of different substrates as the protease-specific mass signatures,
differentiation between different proteases was possible. The unique profiles of the
isobar-coded reporters for each protease were identified.
Another noninvasive sample type for PoC testing in cancer diagnosis is breath
obtained from patients. Perhaps, breath sensing is the least invasive of all diagnostic
strategies. Metabolic reactions in the body generate different volatile organic compounds
(VOCs). These VOCs include hydrocarbons, alcohols, aldehydes, ketones, esters, nitriles
and aromatic compounds. VOCs can be detected in diverse biosamples, such as cancer
cells, blood, urine, skin/sweat35,36 and breath. In fact, besides cancer detection, VOCs are
being used as new diagnostic-based biomarkers for detection of different diseases such as
diabetes,37 Alzheimer’s, Parkinson’s,38 and chronic kidney disease.39 Compared with
healthy individuals, cancer patients express different VOC compositions in their breath
due to the different activities of cancer cells.32 These activities can generate very subtle
changes in the concentration and composition of VOCs in the blood stream. Through
constant exchange between the lung and bloodstream, these subtle changes in VOC
compositions can be transported to the patient’s breath, creating distinct breath signatures
for each cancer type.40 In a healthy breath, the concentrations of several VOCs are
normally in the range of 1–20 p.p.b.12 However, they can be detected in the levels of 10–
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100 p.p.b. in some cancer types. These changes in concentration and composition mixture
of VOCs have made it possible to not only distinguish between the breath of healthy
individuals and cancerous patients, but also differentiate between different types of
cancer.12,32 Previously, VOCs have been detected using gas sensors such as gas
chromatography,41 and ion mobility spectrometry.42 However, the downsides to these
methods are that they are time consuming and require large size, expensive
instrumentation and an expert operator. Moreover, to improve the detection in some of
these devices, capturing and preconcentrating the breath sample is a prerequisite step.43,44
Using the advantages of NPs, a nanoscale artificial nose has been designed by Haick and
co-workers.44 This simple, cost effective and portable sensor is able to detect cancer by
analyzing the VOCs using pattern recognition methods. The nanoscale artificial nose is
capable of identifying different odors even at very low concentrations and subtle
differences.44 The gas sensor is based on an array of highly cross-reactive chemiresistors
made of AuNPs with different organic capping layers. In the resulting sensor, electrical
conductivity was provided by the metallic particles and the organic capping layers create
sites used to capture the analytes.12
Due to the chemical diversity of sensor materials, each sensor of the array shows
a unique response to a certain group of VOCs. This means that the characteristic signal
(electrical resistance) of each sensor in the array changes specifically when exposed to a
specific VOC, which could be the cancer specific odor.44 Consequently, for each cancer
type, a distinct fingerprint is produced from the array of cross-reactive sensors. Using this
gas sensor along with pattern recognition methods, it is possible to discriminate different
cancer types and stages.32,45 It is also worth mentioning that these sensor arrays have
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detection limits of 1–5 p.p.b. or even down to approximately 10 p.p.t.32 Breast, lung,
colon, gastric, colorectal, head-and-neck and prostate cancer are the cancer types that
have been detected using this sensor. Carbon nanotube arrays have been used in a similar
fashion.46,47
It should also be mentioned that although breath sensing is a novel method for
cancer detection, the approach has some limitations. First of all, there are not dramatic
changes in VOCs in the early stages of cancer development; only certain stages will
cause the expression of these VOCs. Second, the conditions and type of foods and drinks
consumed by patients can influence results. The results can also be affected if the patients
have other diseases and are using other medicines.32 Therefore, having sufficient controls
over sample collection is essential when using this type of noninvasive sample.

1.6. Chemometric analysis for data processing
In an array-based sensing strategy, each analyte produces a response from each of
the sensor elements. A multivariate data matrix is obtained from different analytes. As a
result, a large number of generated data has to be analyzed quickly and efficiently to
establish high quantity of fingerprints for identification. These data can be analyzed using
multivariate chemometrics methods. These methods consist of a collection of techniques
that can be used when several measurements are done on each individual analyte. Among
these techniques, principal component analysis (PCA) and linear discriminant analysis
(LDA) are most commonly used. These methods reduce the dimensionality of the data
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sets by extracting the most useful information into new and simpler components called
principal components or canonical factors for LDA.
PCA is one of several multivariate methods that explore patterns in these data.
PCA can determine the general relationship between these data by indicating which
analytes behave similarly (in another words, which analytes belong to a similar group).
While it is useful to know the pattern of these data, identifying which group a new
unknown analyte belongs to is necessary. LDA as a classification (supervised pattern
recognition) method is used for this purpose. In the classification methods, samples with
known identities are used to define the groups (classes). These known sets of samples are
referred to as a training set. The unknown analytes can then be assigned to the predefined
groups using the appropriate classification algorithm.48,49 In the present dissertation, we
extensively utilized LDA for data analysis using SYSTAT software (version 11).

1.7. Dissertation overview
Chemical-nose sensing approach has proved to be an effective strategy for
profiling biorelevant targets such as proteins, glycans, and mammalian cells. However, it
is still a long haul to implement chemical-nose sensors in clinical applications due to
certain challenges discussed in section 1.2. Addressing the challenges associated with
chemical-nose approach is critical to close the gap from basic research to practical
applications. Keeping this goal in mind, my research has focused on fabricating
biocompatible sensor elements for healthcare applications using supramolecular
chemistry of functionalized AuNPs, fluorescent proteins, fluorescent polymers and
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enzymes. This dissertation covers three main themes: cancer therapeutic drug profiling
and cancer diagnostics (Chapter 2-4), environmental toxicity (Chapter 5), and bacterial
detection (Chapter 6) (Figure 1.5).

Figure 1.5. Overview of the dissertation, which includes the use of nanoparticle-proteins,
fluorescent polymers, and nanoparticle-enzyme for healthcare applications.

In the first theme where cancer is the topic of interest, Chapter 2 discusses the
use of supramolecular complexes between cationic AuNPs and three fluorescent proteins
(FPs) for mechanism profiling of chemotherapeutic drugs in a high-content screening
manner. Chapter 3 focuses on the improvement of chemical-nose sensors for cancer
diagnostics based on the 3-channel platform established in Chapter 2. In this chapter, an
innovative supramolecular interaction was used to double the output channels of a sensor
array without additional synthesis. This simple approach provides single-well
identification of cancer cell lysates and opens up a new dimension for array-based sensor
design. The system also uses minimal sample quantity of cell lysates (200 ng, ~1000
cells), making the methodology compatible with microbiopsy technology, a step closer to
18

PoC testing. Chapter 4 presents the transformation of chemical-nose sensor in the PoC
testing field. This chapter discusses the use of a polymer-based sensor to rapidly detect
cancer, based on changes in serum protein levels. Using this approach, only small
quantity of serum sample is needed, allowing a rapid and simple test for cancer
diagnostics. The system was validated using serum collected from different animal
models. This polymer-based sensor holds the potential to stand at the forefront of the
field as it solves the problem of multiple array components typically found in chemicalnose sensors, along with the ease of detection using serum. In this system, only two
polymers were used while maintaining high sensitivity and specificity for cancer
detection, exceeding the standard clinical benchmark.
In the second theme of environmental health, Chapter 5 discusses the extended
use of nanoparticle and green fluorescent protein complexes in a cell-based assay to
detect cellular changes due to hormone disruptor exposures. The use of our sensor in this
application offers a simple way of screening toxic chemicals released into the
environment.
In the third theme of bacterial detection, Chapter 6 discusses the need of a PoC
test for bacteria that can be used in the field. The supramolecular complexes between
nanoparticles and enzymes provide a highly efficient sensor platform for bacteria using
human sense of smell as an output, a convenient way that promotes equipment-free
sensing platform.
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CHAPTER 2
A MULTICHANNEL NANOSENSOR FOR INSTANTANEOUS READOUT OF
CANCER DRUG MECHANISMS
2.1. Abstract
Screening methods that use traditional genomic,1-3 transcriptional,4 proteomic,5,6
and metabonomic7 signatures to characterize drug mechanisms exist. However, they are
time-consuming and require specialized equipment. Here, we present a high-throughput
multi-channel sensor platform that can profile the mechanisms of various
chemotherapeutic drugs in minutes. The sensor consists of a gold nanoparticle (AuNP)
complexed with three different fluorescent proteins (FPs) that can sense drug-induced
physicochemical changes on cell surfaces.8-10 In the presence of cells, FPs are rapidly
displaced from the AuNP surface and fluorescence restored. Fluorescence "turn on" of
the FPs depends on the drug-induced cell surface changes, generating patterns that
identify specific mechanisms of cell death induced by drugs. The nanosensor is
generalisable to different cell types and does not require processing steps prior to
analysis, offering an effective way to expedite research in drug discovery, toxicology and
cell-based sensing.

2.2. Introduction
Rapid determination of the mechanism of drug candidates would greatly facilitate
the discovery and optimisation of new therapeutics,11 particularly in the emerging area of
personalised medicine.12 Recently, “signature”-based profiling of drug mechanisms has
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provided a powerful strategy in drug discovery.1,2,13-16 These screening methods measure
a series of molecular/phenotypic changes of cells/multicellular organisms induced by
chemotherapeutic agents and create a fingerprint that is used as a reference for
uncharacterized compounds. Several signature-based drug screening studies using
traditional intracellular biomarkers1-7 require multi-step processing of cells such as
extracting biomarker1,2,4,5 or labeling cells6,14 and specialized equipment, limiting
adoption of these strategies in rapid drug screening.

Cell surface phenotypes have been utilized in sensing cell states using
nanoparticle-based array sensors.17,18 These sensors follow a hypothesis-free signaturebased strategy14,16,19-22 that allows them to be “trained” to identify diverse bioanalytes.
However, the single channel output of these nanosensors required separate measurements
for each array element, and were unable to differentiate between subtle cell surface
phenotypic differences arising from different cell death mechanisms. We introduce a new
multiplexed

three-channel

sensor

platform

created

through

supramolecular

assembly/disassembly of a functionalised AuNP with three FPs. The simultaneous triplechannel fluorescence transduction provides a ratiometric output that enhances the
accuracy of measurements. Moreover, the information-rich output allows determination
of chemotherapeutic mechanism from a single measurement that provides answers far
faster (minutes) than current methods, and using standard laboratory instrumentation.
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Figure 2.1. Assembly and working principle of the nanosensor. (a) Fabrication of the
three-channel nanosensor (BenzNP–FPs complex). The sensor was prepared by
incubating BenzNP to an equimolar mixture of three FPs at a ratio that was determined
through fluorescence titration. (b) Schematic diagram illustrating the displacement and
fluorescence turn-on of FPs by cell-surface functionalities. (c) Differential affinity of
BenzNP to tdTomato (red), EBFP2 (blue) and EGFP (green) protein. The association
constant (Ka) was determined through titration of equimolar mixture of FPs with BenzNP.

2.3. Results and Discussion
The sensor was generated by non-covalent conjugation of a benzyl headgroupterminated AuNP (BenzNP, Fig. 2.1a) with three FPs (EBFP2, EGFP and tdTomato). The
FPs serve dual roles of exhibiting differential supramolecular affinities with the particle,
and transducing the binding events. BenzNPs were used in the sensor based on our
previous studies that indicated its effectiveness in profiling cell surface phenotypes.17 In
these BenzNP-FP supramolecular complexes, the cationic AuNP binds strongly with the
anionic FPs, resulting in quenching of the FP fluorescence by the particle core. The
binding equilibria between BenzNP and the FPs are altered in presence of cells due to
competitive binding to cell surfaces, resulting in rapid (seconds/minutes) displacement of
FPs from the particle surface with consequent restoration of FP fluorescence (Fig. 2.1b).
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The fluorescence "turn-on" of the three emission channels differs considerably depending
on the signatures of drug-treated cell surfaces.
A key issue in the sensor design is selecting appropriate FPs from the broad range
of variants23 such that they provide reproducible sensor responses. Through tests with
different FP variants we selected a three color FP set for the present study: blue (EBFP2),
green (EGFP), and red (tdTomato). This optimized set of proteins was selected to: (i)
bear net negative charge and feature minimum spectral ‘crosstalk’ with well-separated
excitation and emission spectra, obtaining independent responses from each channel, (ii)
exist as monomers or tandem dimers, simplifying their use in displacement assays
relative to other multimeric analogs, (iii) be photostable, providing reliable outputs.
A second requirement for the FP transducer is differential and reversible
interaction with BenzNP recognition element. We determined the binding parameters by
fluorescence quenching studies that provided the complex stability constant and
association stoichiometry for each FP. It was observed that the binding affinities of
BenzNP and FPs varied over three orders of magnitude (Fig. 2.1c), providing the
differential affinity required for multi-channel output.
We demonstrated the ability of the BenzNP-FP sensor platform to categorize
chemotherapeutic mechanisms using a set of apoptosis- and necrosis-inducing chemical
agents with established mechanisms. These clinical and experimental drugs cover
common mechanisms of therapeutic action in cancer and include several groups with a
common target (macromolecule/pathway). The necrotic agents induce cell death by rapid
plasma membrane rupture,24 which would be expected to generate a strong surface
response. Apoptotic drugs cause programmed cell death that is associated with alterations
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of the plasma membrane including translocation of molecules from the cytosol, as well as
suppression of signaling macromolecules.8-9,10,24 We tested the hypothesis that these
drug-induced cell surface alterations could be rapidly discerned using the nanosensor. We
used BT549 human breast cancer cells (triple negative) as a testbed for profiling
chemotherapeutic mechanisms, since chemotherapy serves as the only systemic therapy
for patients with this type of cancer.25

	
  

Figure 2.2. The nanosensor-based drug screening workflow. The Schematic diagram
illustrates the drug screening workflow. Cells cultured in a 96-well microplate are treated
with chemotherapeutic drugs at their IC50 concentrations for 24 h followed by washing
and incubation the nanosensor. Different drug-treated cells result in distinct cell surface
phenotypes and hence different FP displacement patterns as schematically shown for the
three wells. The bar plot shows differential fluorescence responses for three
representative drugs that may corroborate with the schematic of FP displacement. The
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change in fluorescence along three channels was recorded simultaneously, where I0 and I
are the fluorescence intensity before and after the addition of the sensor to the cells,
respectively. The responses are averages of eight replicate data and the error bars
represent ±standard deviation.

Drug screening studies followed the straightforward protocol shown in Fig. 2.2.
Cell culture, drug treatment, and the sensing studies were carried out in a single well of a
96-well microplate. For consistency, the cells were treated with drugs at their halfmaximal inhibitory concentrations (IC50). We confirmed that the number of cells attached
to the plate for each drug was consistent, ensuring that sensor differentiation arose from
difference in cell surfaces. Notably, the sensor itself did not exhibit any cytotoxicity and
cellular uptake of the particle is negligible within the short experimental time,26 making
our sensing strategy non-interfering in terms of cell behavior.
Initially, we used 15 chemotherapeutics that act through different molecular
mechanisms (Fig. 2.3a) to generate a reference set based on fluorescence responses.
Upon interaction with the drug-treated cells, the sensor generated characteristic
fluorescence fingerprints for the three FPs. The distinct responses along each FP channel
arise from the differential non-covalent interactions such as electrostatic and π–π stacking
with the different biomolecules expressed on the drug-treated cell surfaces. Hierarchical
clustering analysis (HCA) of the fluorescence responses produced seven distinct clusters
(Fig. 2.3a), each corresponding to an individual molecular mechanism. The differential
response pattern in the heat plot demonstrates the sensitivity of the sensor to druginduced cell surface changes.
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Figure 2.3. Screening of chemotherapeutic drug mechanisms using fluorescence
fingerprints. (a) Heat map of the fluorescence response patterns for the reference drug set.
Hierarchical clustering was performed on the log-transformed average of the fluorescence
responses using a correlation metric and average linkage. The resulting dendrograms
show the degree of association of the drugs, as well as each FP. Literature-reported
mechanisms of each drug are listed next to the heat map. (b) Clustering the reference
drugs via LDA of the fluorescence responses. The canonical scores were obtained from
LDA on the fluorescence responses, and were plotted with 95% confidence ellipses
around the centroid of each group. (c) Probabilistic predictions of drug mechanisms
utlising the fluorescence signatures. The p-values were calculated for the averages of
eight replicates using the shortest Mahalanobis distance to the centroid of the nearest
cluster in the reference set that was derived from LDA. A p-value of <0.01 was
considered to be evidence of a “novel” drug mechanism.
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The multidimensional sensor data was quantitatively interpreted using linear
discriminant analysis (LDA). LDA classified the 15 drugs into seven distinct clusters
according to the different pathways/targets of the drugs (Fig. 2.3b). Notably, drugs with
similar molecular mechanisms showed overlapping clusters that were quantifiably
distinguishable from other mechanistic categories. The distinctly separate region between
the apoptotic and necrotic groups demonstrates the ability of the sensor to demarcate
between broader classes of cell death mechanisms. It should be noted that the group size
may determine the broadness of each drug category, with some categories amenable to
further subdivisions.27 We validated the robustness of the LDA method by leave-one-out
cross-validation using a Jackknifed analysis. The between-group (mechanism) crossvalidation accuracy was 99%, indicating the trained classifier to be a reliable and robust
statistical tool. The generality of our strategy was assessed using another cell line with
entirely different genotype/phenotype, for example, pTD cells (murine mammary cancer
cells) that provide an important testbed for exploring therapeutics to regulate oncogenic
epithelial-mesenchymal transition.28 Characteristic fluorescence responses from the drugtreated pTD cells were generated and yielded distinct mechanism-based clusters. These
clusters were somewhat different than that observed with BT549, as expected based on
the geno/phenotypic difference between cell lines (Figure 2.4).
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Figure 2. 4. Drug screening using pTD cells. (a) Heat map of the fluorescence responses
pTD cells when treated with 11 reference drugs, where I0 and I are respectively the
fluorescence before and after the addition of the sensor to the cells. Agglomerative
hierarchical analysis was performed on the averages of the fluorescence responses. The
dendrogram shows degree of association. (b) Linear discriminant analysis of the
fluorescence responses resulted in canonical scores with three discriminants explaining
90.6, 8.5, and 0.9% of total variance and plotted with 95% confidence ellipses around the
centroid of each group (based on the standard error of the mean).
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Figure 2.5. Classification of unknowns outside the initial reference set using BT549
cells. Updated canonical score plot was derived from LDA of the fluorescence responses
from a combination of the initial reference set and the compounds with ‘novel’
mechanisms, and were plotted with 95% confidence ellipses around the centroid of each
group (based on the standard error of the mean). The clusters corresponding to the
‘novel’ compounds are coloured, while the initial reference set compounds are presented
in black.

The ability to identify the mechanism of lead compounds as either known or
novel is a key issue in drug screening. In blinded experiments we assessed seven
anticancer agents that exhibit mechanisms similar to the training set. We predicted the
mechanism of the test compounds by determining the probability of a compound
belonging to the closest reference group using an appropriate F-distribution for the
minimum Mahalanobis distance obtained from LDA. Using a cutoff p-value of 0.01, the
analysis correctly predicted the molecular mechanisms of the seven test compounds
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(Figure 2.3c), demonstrating the capability of the sensor to screen 'real' unknowns. We
next sought to examine if the sensor can identify compounds involving targets/pathways
different from the reference set. Seven compounds with “novel” (i.e. outside the
reference set) cell death mechanisms were tested using the nanosensor. Implementing the
same probabilistic analysis, p-value for each compound was found to be less than 0.01
(Figure 2.3c), indicating that the compounds were far from all the training groups and
could be readily classified as “novel”. Furthermore, a follow-up LDA solution space
including the reference and novel compound set showed clearly distinct clusters, while
the drugs with similar targets paired with each other correctly (Figure 2.5), indicating the
ability to update the training set with ‘new’ mechanistic groups with sufficient resolution.
We tested the robustness of prediction by studying eight parallel replicates of the blinded
unknowns and the novel compounds that resulted in 87.5% (98 of 112 samples) correct
prediction (Figure 2.6). The capability of the sensor to discriminate between learned and
potentially new mechanisms demonstrates the ability of the system to avoid false
positives of mechanism identification. The ability of the sensor to stratify molecularly
targeted drugs such as the HDAC and CDK inhibitors suggests its applicability to broader
class of modern targeted drugs (targeting EGFR, HER2, PDGFR, VEGF, proteasome,
etc)29 that cause up/downregulation of the receptors on cell surfaces.
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Figure 2. 6. Prediction of drug mechanisms on parallel replicates using the triple-channel
sensor. Fluorescence responses from the EBFP2, EGFP, and tdTomato channels were
utilised to perform the statistical analysis. The p-values were derived from F-distribution
on the minimum Mahalanobis distance of each replicate to the centroid of reference
groups calculated by LDA. Based on the p-values, each unknown case (parallel replicate)
was assigned to a mechanistic group of the reference set or regarded as ‘novel’. The
blinded unknowns exhibits cell death mechanisms similar to the reference set, while the
‘novel’ unknowns involve mechanisms completely different from the reference set.

Combination therapy provides a complementary strategy to new drug discovery,
greatly enhancing the efficacy of chemotherapeutics, e.g. by overcoming the drug
resistance of cancer cells.30 Drug combinations produce therapeutic activities
(synergistic, additive, or antagonistic)31 at different ratios of the individual components.
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Thus, a cell surface-based quick screening of the therapeutic activities with respect to
individual drug mechanisms should lead to predicting the contribution of each drug in
their therapeutic combination.32,33

	
  

Figure 2.7. Profiling the mechanisms of drug combinations. (a) Determination of
therapeutic activities of pairwise drug combinations using fractional inhibitory
concentration index (FICI). Correlation of the synergistic combinations of (b) apigenincisplatin, (c) puromycin-cisplatin, and (d) puromycin-apigenin with the single-drug
mechanistic categories. The canonical scores were calculated for the pairwise
combinations with the mechanistic groups that contain the single-drug components
forming the combinations. The LDA-derived scores from the fluorescence responses
were plotted with 95% confidence ellipses around the centroid of each group. The
mechanistic categories consist of several drugs with the same mechanism, Topo II
inhibition: daunorubicin, etoposide, doxorubicin, and apigenin; DNA crosslinking:
cisplatin, chlorambucil, and oxaliplatin; Protein synthesis inhibition: anisomycin, emetin,
and puromycin. Each drug was used in eight replicates.
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We demonstrated the ability of our sensor to determine mechanistic correlation
between individual drugs and their combinations using three apoptotic drugs: apigenin
(APG), puromycin (PUR), and cisplatin (CSP). We utilized fractional inhibitory
concentration index34 to select the synergistic drug combinations. Interestingly, pairwise
interactions of the drugs showed synergy or additivity depending on the ratios of the
individual drugs (Fig. 2.7a). Comparison of the APG-CSP synergistic pairs with the
single-drug components indicated that both the combinations exhibited a DNA
crosslinking-like mechanism, consistent with previous observations35 of APG enhancing
the cytotoxicity of CSP. The LDA scores quantified the similarity of the signatures of
APG-CSP synergistic combinations to CSP with p>0.01 (Fig. 2.7b). Similarly, the
signature of the PUR-CSP(1:3) combinations revealed its close proximity to protein
synthesis inhibition-like mechanism (Fig. 2.7c), suggesting CSP potentiating the PURinduced cytotoxicity. However, PUR-CSP(1:1) and the PUR-APG synergistic
combinations were classified quite far (p<0.01) from their single-drug components (Fig.
2.7c,d), indicating a mechanistically distinct cell surface phenotypic change that provides
a potentially new therapeutic strategy. These representative examples indicate that the
sensor can provide an information-rich strategy for predicting the mechanisms of drug
combinations.

2.4. Conclusions
In summary, we demonstrated the creation of a novel multichannel sensor based
on non-covalent supramolecular complexes. This sensor uses an engineered nanoparticle
and three different FPs to provide a three-channel sensor that can be “trained” to detect
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subtle changes in cell surface properties. This biocompatible nanosensor can identify
specific mechanisms induced by different chemotherapeutic agents, using a single well of
a microplate, making this strategy applicable to massively high-throughput screening.
The simplicity and effectiveness of the system underscores its potential to accelerate drug
discovery, greatly facilitating the development of new therapeutics and drug “cocktails”.
This sensor system also provides a potential way forward for toxicology, providing a
viable method to classify the tens of thousands of commercial chemicals for which no
data are available.

2.5. Experimental section
2.5.1. Fluorescence titrations. In the fluorescence quenching experiment, an
equimolar solution of the three FPs (100 nM each) was titrated with various
concentrations of BenzNP ranging from 0 to 300 nM. The excitation/emission/cut-off
wavelengths were 380/450/435, 475/510/495, and 550/585/570 nm for EBFP2, EGFP
and tdTomato, respectively. The change of fluorescence intensity at the respective
emission maxima was recorded on a Molecular Devices SpectraMax M3 microplate
reader at 25 °C. Decay of fluorescence intensity of each FP was observed with increasing
NP concentration. Nonlinear least-squares curve fitting analysis was employed to
estimate the binding constant (Ka) and association stoichiometry (n) using a 1:1 binding
model (Figure 2.8).36,37
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Figure 2.8. Titration of FPs with BenzNP. Fluorescence titration of an equimolar mixture
of the three FPs by BenzNP. The emissions for each FP were measured independently at
the corresponding emission wavelengths. The data points are averages of three replicates
and the error bars represent the ±standard deviations. The black solid lines through the
data points represent the best curve fitting using the model of single set of identical
binding sites.

2.5.2. Sensor preparation. First, a FP solution was prepared by mixing the FPs at
the final concentration of 100 nM (for each FP). The BenzNP-FP sensor was generated
by incubating the FP solution with BenzNP (at the final concentration of 150 nM) for 30
min in 5 mM sodium phosphate buffer (pH 7.4). The FP and BenzNP-FP solutions were
maintained in the dark to minimise photobleaching of the FPs, if any. This conjugate was
then added to the drug-treated cells for screening studies.
2.5.3. Cell culture. BT549 cell line was purchased from ATCC (ATCC® HTB122™). pTD cell line38 was donated by Prof. D. Josph Jerry. BT549 cells were cultured in
DMEM media supplemented with 10% FBS and 1% antibiotics. Cells were grown in a
humidified atmosphere containing 5% CO2 at 37 °C. The TD cells were cultured in
DMEM high glucose media supplemented with 10% FBS and 1% antibiotics. At ~80%
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confluence, cells were trypsinised and plated in 96-well plates (Greiner black-and-clear
bottom) and cultured for the next studies.
2.5.4. IC50 of the drugs. The IC50 values of the drugs were determined by
Alamar blue assay. Cells were seeded at 10,000 (BT549 cells) or 15,000 (pTD cells) per
well in 96-well microplates (Greiner black-and-clear bottom). After 24 h, the cells were
washed twice with phosphate buffered saline (PBS) and treated with drugs at different
concentrations. The drug treatment was continued for 24 h for all the drugs except
hydrogen peroxide and sodium nitroprusside for which 5 h treatment was effective. Drug
treatment was done in cell culture media lacking antibiotics. After the drug treatments,
cells were washed with PBS twice and the percentage cell viability was determined by
using Alamar blue assay following the manufacturer’s protocol (Invitrogen). The IC50
values were determined by fitting the data using a dose response model with variable Hill
slope built in OriginPro 8.5 (Figure 2.9).

	
  

Figure 2.9. Determination of IC50 value of the single cytotoxic compounds.
Representative dose response curves of (a), apigenin, and (b, puromycin using 10,000
BT549 cells following 24 h drug treatment. The IC50 values were determined by fitting
the data (the red line) using dose response model with variable Hill slope built in
OriginPro 8.5. The data are averages of three replicates and the error bars represent the
±standard deviation.
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Dose response studies for combination of drugs were followed in a similar
method of single drug. Three drugs (puromycin (PUR), cisplatin (CSP), and apigenin
(APG)) were chosen arbitrarily to study the drug combinations (Fig. 4). To determine the
IC50 values, two drugs of a combination were added to confluent cells one by one at 1:1,
1:3, and 3:1 ratio with varying concentrations (Supplementary Table 2). The
concentrations of drugs used were same for all the different combinations (PUR-CSP,
PUR-APG, and APG-CSP). The IC50 values were determined by fitting the data using the
same dose response model (Figure 2.10).

	
  

Figure 2.10. Determination of IC50 value of the combination of drugs. Representative
dose response curves of the drug combinations (a), PUR-CSP(1:3), (b), PUR-CSP(1:1),
and (c), PUR-CSP(3:1) using 10,000 BT549 cells after 24 h of drug treatment. The IC50
values were determined by fitting the data (the red line) using dose response model with
variable Hill slope built in Origin 8.5 program. The data are averages of three replicates
and the error bars represent the ±standard deviation.
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2.5.5. Drug screening studies. The drugs were purchased from VWR
International, Sigma-Aldrich, and Tocris Bioscience. First, 10,000 (for BT549 cells) or
15,000 (for pTD cells) cells/well were seeded in 96-well Greiner black-and-clear bottom
microplates and allowed to grow in their respective culture media at 37 °C and 5% CO2
for 24 h. Then, cells were washed twice with PBS and treated with the drugs at their
respective IC50 concentrations. The drug treatment was continued for 24 h for the
individual drugs as well as their combinations (except for hydrogen peroxide and sodium
nitroprusside, which were treated for 5 h). Cells were then washed three times with PBS
and incubated with the sensor for 15 min before taking the reading. Then, 200 µL of the
BenzNP-FP conjugate was loaded into 96-well plates containing drug treated cells to be
analyzed. After 15 min of incubation with the sensor, fluorescence intensities were
monitored for each FP using a plate reader (Molecular Device Spectramax M3) at 25 °C.
Appropriate

filters

were

excitation/emission/cut-off

used

to

wavelengths

collect
were

emissions

from

380/450/435,

each

FP.

The

475/510/495,

and

550/585/570 nm for EBFP2, EGFP and tdTomato, respectively. Fluorescence responses
were log2-transformed before employing the statistical analyses.
2.5.6. Determination of FICI. The fractional inhibitory concentration index
(FICI) was calculated using the following equation based on Loewe additivity:39,40

	
  

where, [A]C and [B]C are the concentrations of drug A and B in the combination
associated with a particular level of effect, e.g., IC50, and [A]E and [B]E are the
concentrations of A and B when used singly to produce the same level of effect. FICI < 1
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indicates synergism, while 1 ≤ FICI < 4 indicates additivity, and FICI ≥ 4 indicates
antagonism.
2.5.7. Hierarchical clustering analysis. Hierarchical clustering analysis (HCA)
is an unbiased clustering approach. HCA of the average data set was performed using the
hclust function of the stats package of R assuming a complete linkage method.41 hclust
begins with each case serving as its own cluster; at each step in the clustering process, the
two most similar cases or clusters are joined; the process iterates until all cases fall into a
single cluster. HCA allows cases with mechanisms outside the reference set to be
identified as novel, if they are dissimilar from the other cases in the set; in this case, they
are linked to the other cases/clusters relatively high in the dendrogram.
2.5.8. Linear discriminant analysis. The raw fluorescence response data matrix
was processed by classical linear discriminant analysis (LDA) using SYSTAT software
(version 11.0, SystatSoftware, Richmond, CA, USA). In LDA, all variables were used in
the model (complete mode) and the tolerance was set as 0.001. The raw fluorescence
response patterns were transformed to canonical patterns where the ratio of between-class
variance to the within-class variance was maximized, where the classes were defined as
the drug mechanisms in the reference set. This defines the LDA solution space. To
identify the unknown (blinded) samples, we first re-ran LDA on the reference set using
the lda function in the MASS package42 of R; these results replicated the SYSTAT
analysis. Predicted classifications for the blinded samples were then obtained using the
predict.lda function that uses the fluorescence response patterns of each new case to
compute the Mahalanobis distance of that case to the centroid of each mechanism cluster
in the LDA solution space (Fig. 3b). Blinded cases are predicted to belong to the closest
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mechanism class, defined by the shortest Mahalanobis distance. Because some distance is
always shortest, LDA is incapable of identifying blinded or completely unknown samples
as having novel mechanisms. However, by considering the expected distribution of
Mahalanobis distances under these conditions, cases can be identified as outliers if they
fall far from the closest centroid (i.e., have an associated p-value < 0.01).
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CHAPTER 3
CANCER CELL DISCRIMINATION USING HOST-GUEST ‘DOUBLED’
ARRAYS
3.1. Abstract
We report a nanosensor that uses cell lysates to rapidly profile the tumorigenicity
of cancer cells. This sensing platform uses host-guest interactions between cucurbit[7]uril
(CB[7]) and the cationic headgroup of a gold nanoparticle (AuNP) to non-covalently
modify the binding of three fluorescent proteins of a multichannel sensor in situ. This
approach doubles the number of output channels to six, providing single-well
identification of cell lysates with 100 % accuracy. Significantly, this classification could
be extended beyond the training set, determining the invasiveness of novel cell lines. The
unique fingerprint of these cell lysates required minimal sample quantity (200 ng, ~1000
cells), making the methodology compatible with microbiopsy technology.

3.2. Introduction
Rapid methods for geno- and phenotyping cells are crucial for cancer prognosis
and the design of therapeutic strategies for precision medicine.1,2 Discrimination between
healthy and cancerous cells, and then geno/phenotyping to determine whether the cancer
is a slow-growing variant or a highly aggressive form are all important for optimal
treatment.3,4 The cell proteome provides a significant resource for determining cell
tumorigenicity.5,6

Traditionally, biomarker-based approaches employing proteomics

techniques such as electrophoresis and mass spectrometry have been used to detect
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changes in cell state.7-9 These methods, however, require prior knowledge of the tumor,
and are often not sensitive to subtle changes in proteomic signatures. In contrast, arraybased ‘chemical nose’ sensing provides an alternative strategy uses selective receptors to
generate multiple output channels that are used to create patterns (training sets),
analogous to olfaction.10-12 These outputs are then used to build a global diagnostic
pattern that can be used to rapidly identify individual small molecule13-15 and
biomacromolecular analytes.16,17 More recently, array-based sensing has been used to
profile complex biosystems,18-20 including the use of cell lysates to rapidly profile
geno/phenotype of cells and tissues for cancer diagnosis.21
The traditional application of array-based sensing protocols uses spatially
separated sensor units each with their own recognition element to provide the multiple
outputs required for pattern generation.22-26 Some studies report materials that have
multiple optical properties that can be employed to give multiple channels within a single
receptor;27-31 however, even in this format, each optical signal must still be measured
separately. In recent research, an alternative strategy employing a single nanoparticle
recognition element with three different transducers (red, green, and blue fluorescent
proteins (FPs)) was used to generate multi-channel outputs.

This approach greatly

simplifies the sensor system physically, facilitating ‘one-well’ discrimination of complex
biosystems, including identification of bacterial biofilms,32 mammalian cells,33,34 and
determination of drug mechanisms.35 A key challenge with this strategy, however, is
generation of sufficient non-interfering channels (e.g. fluorescent emission wavelengths)
for effective pattern generation.
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Host-guest chemistry is a versatile tool for noncovalent modification of polymers
and nanomaterials, altering the structure and concomitantly the behavior of these
materials.36-39 This approach has been widely used in many applications, including
imaging,40 therapeutic delivery,41 and sensing.42

We hypothesized that a host-guest

strategy could be used to increase the information content of array-based sensing
platforms, facilitating their use in cancer identification and typing. In our approach, we
used

noncovalent

modification

of

a

cationic

benzylammonium-functionalized

nanoparticle with a complementary cucurbit[7]uril (CB[7]) moiety (Figure 3.1).43,44 This
binding modulates the interaction of the particle with both the fluorescent protein
transduction elements and the cell lysate analytes. This change in competitive binding
effectively doubles the number of output channels from three to six while maintaining the
one-well configuration. This increased information content allowed facile discrimination
of cells by their tumorigenicity. Significantly, this classification could be extended
beyond the training set, determining the invasiveness of novel cell lines. Full
differentiation of cell types was achieved with as little as 200 ng of protein (~1000 cells),
demonstrating the potential of this method for microbiopsy-based cancer diagnostics.45
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Figure 3.1. Six channel-output in a single well. The fluorescence of FPs is quenched
when the BenzNP-FP complexes are formed. Upon addition of cell lysates, three
emission channels are obtained from the released FPs. In the same well, CB[7] is added
to obtain three additional channels from the three FPs as a result of changed interactions
between the analyte and newly formed complex, BenzNP-CB[7].
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3.3. Results and Discussion
The sensor consists of two supramolecularly-related recognition receptors:
BenzNP and BenzNP-CB[7]. BenzNP can bind to the CB[7] host molecule to rapidly
form host-guest complexes.46 The binding events of BenzNP and BenzNP-CB[7] with the
lysates are transduced by three fluorescent proteins: blue (EBFP2) (B), green (EGFP)
(G), and red (tdTomato) (R). In the presence of BenzNP, the fluorescence intensity of
FPs is quenched. Different amounts of FPs are then released after the addition of cell
lysates due to their competitive binding for the particles, generating channels 1-3. Hostguest interactions between CB[7] and BenzNP47

create the second recognition

receptor.48,49 The addition of CB[7] triggered a drastic change in fluorescence intensity
of the three FPs, indicating a stronger interaction of BenzNP-CB[7] complexes to FPs
than the BenzNP,50-52 generating channel 4-6. CB[7] is a good synthetic receptor for
peptides and proteins, which might contribute to the enhanced quenching ability of
BenzNP–CB[7] toward FPs in the presence of lysates.53 To ensure that the fluorescence
changes are induced by the interaction of BenzNP-CB[7] with cell lysates and not from
any changes of FPs themselves, we tested the effect of CB[7] and lysates on FPs alone
and found that they do not affect fluorescence intensity of FPs (Figure 3.2).
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Figure 3.2. Effects of (a) CB[7] and (b) cell lysates on three fluorescence proteins. Both
CB[7] and 200 ng of cell lysates did not change the fluorescence intensities of the three
fluorescence proteins significantly. Each value is an average of three replicates.

The first step in our sensing was to determine the appropriate conditions for
converting Benz-NP to BenzNP-CB[7]. The appropriate stoichiometry of CB[7] and
BenzNP was determined by isothermal titration calorimetry (ITC) and the 100/1 ratio of
CB[7]/BenzNP was used throughout our sensing experiments (Figure 3.3). We also
measured the saturation point of CB[7]/BenzNP using fluorescence titration assay of
BenzNP-FP complexes preincubated with 200 ng cell lysates and varied concentrations
of CB[7]. The same ratio of 100/1 of CB[7]/BenzNP was observed for this assay (Figure
3.4).
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Figure 3.3. Isothermal titration calorimetry (ITC) measurements of BenzNP with CB[7].
The saturation ratio of CB[7]/BenzNP was determined to be 100/1.
	
  

	
  

Figure 3.4. Fluorescence titration of BnzNP-FPs with lysates with varying concentrations
of CB[7]. The saturation ratio of CB[7]/BenzNP was determined to be 100/1.
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As an initial test of our method, five human cancer cell lines with different
tissue/organ origins were used: MCF-7 (breast), SKOV3 (ovarian), Raji (blood), NCIH1299 (lung), HEK239T (kidney) (Table 1). We used fluorescence spectroscopy to
generate "fingerprints" for the cell lysates obtained from the cultured cell lines. In
practice, cell lysates were added to the BenzNP−FPs complex, readings taken, then
CB[7] was added to generate BenzNP−CB[7] in situ, with subsequent readout. These
fluorescence outputs were analyzed by linear discriminant analysis (LDA). Cluster
separation on an LDA plot was generated based on their standardized Mahalanobis
distance: the greater the distance the lower the probability of misclassification. When
only three channels are used, there is substantial overlap among different cell lines,
especially NCI-H1299, SKOV3, MCF7, and Raji for the BenzNP-FPs channels (Figure
3.5a), and overlaps between NCI-H1299 with HEK-239T, and SKOV3 with MCF-7 for
the BenzNP-CB[7] channels (Figure 3.5b). However, when all 6 channels are combined,
all five cell lines are well separated (Figure 3.5c).

Table 3.1. Features of five cancerous human cell lines with different tissue origins.

One critical step in chemical-nose sensing is to challenge its reproducibility. For
this purpose, we revalidated our sensor by using an unknown set of all five cell lines (5
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cell lines × 8 replicates = 40 unknown cases). We were able to predict the identities of the
38 out of 40 unknown cases with 95 % correct unknown identification (% CUI) in a
single-well configuration using 6-channel system. When there are only three channels,
the % CUI drops drastically (Figure 3.5d).
An important challenge in cancer therapy is determining whether tissue/cells are
benign or cancerous; if they are cancerous, then whether or not it has the ability to
metastasize to other organs. We chose three different human breast cell lines to test our
host-guest doubled array sensor: MCF10A (normal), MCF-7 (cancerous), MDA-MB-231
(metastatic) (Figure 3.6a). The three cell lines also show differential fluorescence patterns
that are clustered separately by LDA when 6 channels are used (Figure 3.6b). Similar
trend is observed in the % CUI of these three human breast cell lines where the six
channel system gives much better unknown identification of 96 % (23 out of 24 samples)
compared to the three channels (Figure 3.6c).
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Figure 3.5. Five human cancerous cell lines were clustered using Linear Discriminant
Analysis (LDA) with the fluorescence responses from a) only three channels: BenzNPFPs and b) BenzNP-CB[7], c) all six channels. d) Correct unknown identification
percentage of three sensing systems. Unknown population is 40 samples for five cell
lines.

To further validate our sensor with a more stringent test, we employed isogenic
cell lines derived from BALB/c mice. These cells can provide a testbed for our sensor by
avoiding the issue of individual-to-individual geo/phenotypic variation since they share
the same genetic background but have different histological stages, as characterized in
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vivo. TM40A has undetectable tumorigenicity (0 %), TM9 generated tumors in 38 % of
the cases, while MC7-L1 quickly developed tumors and became highly metastatic in
100% of tested mice (100% tumor) (Table 3.2). These challenging isogenic cell lines are
also differentiated using our six channel system (Figure 3.7a). However, when only three
channels are used, there is always some level of overlap between the non-tumorigenic
(TM40A) and the low-tumorigenic group (TM9), while the high tumorigenic cluster is
highly separated from the others. This indicates biological similarity between the nontumorigenic and the low-tumorigenic samples. This same trend is also observed in the
fluorescence heat map, analyzed by hierarchical clustering analysis (HCA) using six
channels, where TM40A while is separated from TM9, they still share the same sub
branch with each other and are much more different than the high-tumorigenic cell line
MC7-L1 (Figure 3.7b). These results of 10 cell lines confirm the benefit of increasing the
number of channels in chemical-nose sensing system, not just for the classification of
each group but most importantly, the accuracy in unknown identification (Figure 3.7c).
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Figure 3.6. Three human breast cell lines with (a) different cell status were clustered
using Linear Discriminant Analysis (LDA) with the fluorescence responses from (b) six
channels. (c) Correct unknown identification percentage of three sensing systems.
Unknown population is 24 samples for three cell lines.

Table 3.2. Features of five breast cell lines.

Reference
cell lines
Cell lines outside
of reference

#

Cell line

1
2
3
4
5

TM40A
TM9
MC7-L1
FSK7
MC4-L2

Tissue
origin
Breast
Breast
Breast
Breast
Breast

Cell status
Normal
Low-tumorigenic
High-tumorigenic
Low-tumorigenic
High-tumorigenic

To further validate the versatility of our 6-channel system, we cultured two
additional cell lines that have similar histological outcomes with the cell lines in our
reference set but different identities. These cell lines are FSK7 (low-tumorigenic) and
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MC4-L2 (high-tumorigenic).54,55 The fingerprints of these two cell lines were compared
to the reference set to predict their histological outcomes. LDA plots show the overlap of
each unknown cell line with their corresponding tumorigenicity with 100 % accuracy
(Figure 4, Table S6). This result strengthens the sensor reliability in identifying clinically
relevant features of cells. Notably, translating results from one cell line to use as
reference for other novel cell lines has not been achieved previously with chemical-nose
sensors.

	
  

Figure 3.7. Three isogenic breast cell lines derived from BALB/c mice were clustered
using Linear Discriminant Analysis (LDA) with the fluorescence responses from a) six
channels. b) Heat map of the fluorescence response patterns for the reference set using
six channels. Hierarchical clustering was performed on the normalized average of the
fluorescence responses, where I0 is the initial fluorescence intensity of the sensor and I is
the final fluorescence intensity of the sensor after lysate incubation. c) Correct unknown
identification percentage of three sensing systems. Unknown population is 24 samples for
three cell lines.
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Figure 3.8. (a) Unknown cell lines were clustered with the established reference cell
lines via LDA by using the fluorescence responses from all six channels. (b) The correct
unknown identification percentage of FSK7 and MC4-L2 are both 100 %.

3.4. Conclusions
In summary, we have used host-guest chemistry to double the information content
of an array-based sensor for cancer diagnostics. The sensor was able to readily
discriminate phenotypic changes among cells based on their complex proteomic
signatures associated with different histological outcomes. The unique fingerprint of
complex cell lysates can be obtained in a single well with minimal sample quantity (200
ng of total proteins), minimizing biopsy size, reducing the invasiveness of the
methodology. Significantly, the classification of this host-guest-based sensor could be
extended beyond the training set, determining the invasiveness of unknown cell lines that
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have similar histological outcomes. In a broader context, this host-guest-based chemical
nose sensor presents a general means of increasing dimensionality in array-based sensors.

3.5. Experimental section
3.5.1. Cell culture. Raji cell line was donated by Professor Rachel M. Gerstein
(Department of Microbiology and Physiological Systems, University of Massachusetts
Medical School). MCF10A, TM40A, TM9, MC7-L1, FSK7, and MC4-L2 cell lines were
donated by Professor Joseph Jerry (Department of Veterinary and Animal Science,
University of Massachusetts Amherst). Raji was cultured in RPMI-1640 media
supplemented with 1% glutamine, 1% non essential amino acid, 1% Sodium Pyruvate, 50
µM β-mercaptoethanol, 10% FBS, and 1% antibiotic solution. MCF10A was cultured in
DMEM/F-12 media supplemented with 5% horse serum, 1% penicillin/streptomycin,10
µg/ml insulin, 20 ng/ml EGF, 0.5 µg/ml hydrocortisone, and 100 ng/ml cholera toxin.
TM40A, TM9, MC7-L1, FSK7, MC4-L2 were cultured in DMEM:Ham’s F12 (1:1)
media supplemented with 2% ABS, 25 mM HEPES, 10µg/ml insulin, 5 ng/ml EGF, and
1% antibiotics. MCF-7, SKOV3, HEK239T were cultured in DMEM media
supplemented with 10% FBS and 1% antibiotics. MDA-MB-231 was cultured in
DMEM/High Glucose media supplemented with 10% FBS and 1% antibiotics. NCIH1299 was cultured in RPMI-1640 media supplemented with 10% FBS and 1%
antibiotic solution. All cells were grown in a humidified atmosphere containing 5% CO2
at 37 °C.
3.5.2. Cell lysate preparation. At about 80% confluence, cells were washed with
ice cold PBS to remove all the loosely bound serum proteins in the media before adding
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1mL of protease inhibitor-contained lysis buffer (0.15 mmol/L NaCl, 5 mmol/L EDTA,
1% Triton-X 100, 10 mmol/L Tris-HCl (pH 7.4), plus half a tablet of complete protease
inhibitor cocktail in 50 mL of buffer (Roche Diagnostics GmbH)). These cell flasks were
stored at 4 oC for 15 minutes to ensure the lysis of the cell membrane. After 15 minutes,
the cells were scraped with a sterile scraper, transferred to an eppendorf tube to be
centrifuged down at 4 oC for 20 minutes at 14,000 rpm. The supernatant which contains
cellular proteins were then quantified using BCA assay. For cell lysate sensing
experiment, 200 ng of total protein from each cell line was used.
3.5.3. Fluorescence titrations. In the fluorescence quenching experiment with
BenzNP, an equimolar solution of the three FPs (100 nM each) was titrated with various
concentrations of BenzNP ranging from 0 to 300 nM. The excitation/emission/cut-off
wavelengths were 380/450/435, 475/510/495, and 550/585/570 nm for EBFP2, EGFP
and tdTomato, respectively. The change of fluorescence intensity at the respective
emission maxima was recorded on a Molecular Devices SpectraMax M3 microplate
reader at 25 °C. For the CB[7] titration with BenzNP-FPs complex, the optimized
concentration of the sensor complex (150 nM BenzNP and 100 nM each FPs) was first
mixed together and 200 µL of this mixture was added into the 96 well plate. To test the
releasing capability of FPs, 200 ng of Lipase (prepared in the same lysis buffer as other
cell lysates) was added into BenzNP-FPs mixture and this mixture was incubated for 15
minutes. Then, 10µL of a series of CB[7] concentrations was added into the previous
mixture to determine the ratio of CB[7] and BenzNP that can quench FPs. Nonlinear
least-squares curve fitting analysis was employed to estimate the binding constant (Ka)
and association stoichiometry (n) using a 1:1 binding model.
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3.5.4. Sensing studies. BenzNP-FPs conjugates were generated by mixing 150
nM of BenzNP and each FPs (100 nM) in 5 mM sodium phosphate buffer (pH 7.4). Then,
200 µL of BenzNP-FPs complex solution was loaded into a 96-well microplate, and
initial fluorescence intensities (I0) of the quenched complexes were measured at
450/510/585 nm. Then, 200 ng of each cell lysates was incubated with these complexes
to determine the changes in fluorescence of the BenzNP-FPs complexes and establish the
first three channels. After that, 10 µL of CB[7] was added into the 96 well plate using a
Molecular Devices SpectraMax M3 microplate reader (at 25 oC).
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CHAPTER 4
SIMPLE AND ROBUST POLYMER-BASED SENSOR FOR RAPID CANCER
DETECTION USING SERUM
4.1. Abstract
We report a polymer-based sensor that rapidly detects cancer, based on changes in
serum protein levels. This sensing platform utilizes the fluorescence signals from two
charge-complementary polymers, and their fluorescence resonance energy transfer
(FRET) to provide three ratiometric outputs. This simple system rapidly identifies cancerbearing mice in transgenic and xenograft mouse models. This sensor was validated by
accurate prediction on blinded unknown samples, demonstrating the robustness of the
approach. Taken together, this polymer-sensing platform provides an attractive strategy
for point-of-care testing.

4.2. Introduction
Effective treatment of cancer requires early detection, making the creation of
rapid and inexpensive sensing systems important for both health and healthcare cost
reasons.1-3 Serum presents a minimally invasive target for the design of cancer
diagnostics. A broad range of protein level in serum changes during tumor development.35

Most techniques used for detection of cancer using serum focus on specific biomarkers.

Enzyme-linked immunosorbent assay (ELISA) remains the method of choice.6,7 ELISA,
however, has limitations in sensitivity for low-abundance biomarkers. Most importantly,
many cancer types do not have ideal biomarkers, due to widely different baseline
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expressions of targeted biomarkers in the population, often leading to false positives and
negatives in these tests.1b,8-10 Serum analysis can also be done by gel electrophoresis,
coupled with mass spectrometry, but analysis time, quantification challenges, and
expensive instrumentation are an issue.11-13
‘Chemical noses/tongues’ provide an alternative to biomarker-based sensing and
do not require previous knowledge of the analytes; instead they ‘train’ the sensor system
to recognize analytes based on the overall subtle changes in complex mixtures.14-16
Array-based sensors are composed of recognition and transduction elements, work hand
in hand to establish a fingerprint for each analyte. An array of five gold nanoparticles
detects proteins in human serum. Their binding was transduced by green fluorescent
proteins (GFPs).17 Array-based sensors combine recognition and transduction, such as
magnetic

glyconanoparticle

arrays18

(MGNP)

and

nanomaterial-assisted

chemiluminescence.19 Overall, chemical noses and tongues are able to identify proteins,17
carbohydrates,20 and mammalian cells21-23 in addition to white wines, fruit juices and
non-steroidal antiinflammatories.24-26
Simplicity and scalability are important attributes for point of care (POC)
diagnostics.27 To address this concern, we have directed our focus on a simple but robust
polymer-based sensor system for profiling serum for cancer diagnostics. This system is
based on the fluorescence signals of two charge-complementary conjugated fluorescent
polymers and their fluorescence resonance energy transfer (FRET) to provide three
ratiometric outputs. This polymer-only platform utilizes the structural diversity,
fluorescence efficiency, stability, and scalability of conjugated polymer “molecular
wires”28-32 to detect cancer in sera of cancer-bearing mice. The transgenic and xenograft
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animal models used in this study plausibly recapitulate some of the clinically relevant
events seen in individuals with cancer.

	
  

Figure 4.1. Schematic illustration of FRET-based polymer sensor for serum sensing. (a)
Two polymers with opposite charges form supramolecular complexes through
electrostatic interactions, generating FRET responses. The fluorescence intensities of two
polymers and FRET responses are interfered with the addition of serum proteins. (b)
Chemical structures and characteristics of polymers used in the study. Mn: numberaverage molecular weight; Mw: weight-average molecular weight; PDI: polydispersity
index.

4.3. Results and Discussion
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We designed two different backbones for our donor and acceptor polymers to
provide an optimum FRET-based sensor, which is composed of polyfluorene sulfonate
(PFS) and poly(p-phenyleneethynylen) (PPEs), respectively. Upon addition of serum, the
fluorescence of each polymer, as well as their FRET process, are modulated due to the
binding of serum proteins to the polymers. These fluorescence fingerprints are analyzed
by linear discriminant analysis (LDA) to create a reference set (training set) and predict
future unknown samples (Figure 4.1). Upon excitation at the PFS absorbance band of 365
nm, the complexes PFS-PPE1 and PFS-PPE2 exhibit efficient FRET from PFS to PPEs.
We observed the decreased fluorescence emission at 420 nm and sensitized emission at
480 nm for PPE1 and 482 nm for PPE2 (Figure 4.2).
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Figure 4.2. Emission spectra as a function of concentration of (a) PPE1 for the PFSPPE1 pair and (b) PPE2 for the PFS-PPE2 pair. Spectra were recorded at an excitation of
356 nm for each pair in phosphate buffer saline (PBS), at pH 7.4.

Table 4.1. Characteristics of eight proteins in PBS
#

Proteins

1
2
3
4
5
6
7
8

Transferrin
Fibrinogen
Human Serum Albumin
α1-antitrypsin
Myoglobin
Lipase
Alkaline Phosphatase
Cytochrome C

Charge at
pH 7.4
Neutral
Neutral
+

Isoelectric
point
6.1
5.5
5.2
4.6
7.2
5.6
5.7
10.7
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Molecular weight
(kDa)
80
340
69.4
52
17
58
140
12.3

	
  

Figure 4.3. Fluorescence response from PFS-PPE1 sensor after eight protein incubation
in PBS.
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Figure 4.4. Comparison between two polymer pairs: PFS-PPE1 and PFS-PPE2. (a) Initial
fluorescence spectrum (black) of the PFS-PPE1 complex and final spectrum upon
incubation with pure calf serum (red). (b) LDA plot of the PFS-PPE1 complex responses
to eight proteins in PBS at 10 µg/ml with a 100 % correct classification. HSA is Human
Serum Albumin. The analysis resulted in canonical scores with two discriminants
explaining 79.8 %, and 16.0 % of total variance and was plotted with 95% confidence
ellipses around the centroid of each group. (c) Performance comparison between PFSPPE1 and PFS-PPE2 FRET pairs, where A is the classification accuracy of eight proteins
detected in PBS, B is the correct unknown identification (CUI %) of these eight proteins
in PBS, C is the classification accuracy of normal and cancerous mouse serum samples
from the transgenic lung cancer model at different concentrations, and D is the CUI % of
these mouse serum samples at different concentrations. (d) Limit of detection of PFSPPE1 complex in detecting normal and cancerous mouse serum samples from the
transgenic cancer model at 1, 5, 10, and 20 mg/ml total protein concentrations, in the
order from left to right.
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After we determined the ratio of PFS and PPEs with a suitable FRET response,
each pair was tested in calf serum, the addition of which caused a decrease in sensitized
PPE fluorescence and an increase in the donor PFS fluorescence. This observation
indicated dissociation of the complexes due to binding of serum proteins towards these
polymers. These FRET-based sensors identify eight different proteins dissolved in
phosphate buffer saline (PBS, pH 7.4) (Table 4.1). We observed distinct fluorescence
changes for all eight proteins from each polymer pair, PFS-PPE1 and PFS-PPE2 (Figure
4.3). LDA plots show correct classifications of different proteins (100 % and 97.0 %,
respectively) but also successfully identified blinded unknown samples (98.4 % and 89.0
%, respectively) (Figure 4.4b, c) and that in a matter of minutes.

Table 4.2. Characteristics of tumor mouse models

Model type

Mouse
strain

Cell
line

Injection
location

Tumor
induction
time
(days)

#
Control
s

#
Cancerbearing
mice

Transgenic
lung cancer
model

129/Sv
p53R172HΔg/
+
K-rasLA1/+
mice

N/A

N/A

100-300

5

5

Experiment
al lung
cancer
model

NIH-III
(nu/nu;
beige/beige
) mice

H1299

Intracardia
c route

55-120

5

5

We validated the sensor using a more challenging test bed: cancer-bearing mice
and healthy controls from a transgenic lung model (Table 4.2), established by mutations
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in the Kras and p53 genes. We determined the total serum protein concentration
necessary for the assay. Four different concentrations of normal and cancerous sera from
the transgenic lung model were prepared and titrated with each sensor. The LDA plot
shows separation of normal (upper) versus cancerous (lower) serum samples with a shift
from left to right that associates with low to high concentrations of total proteins: 1, 5, 10,
and 20 mg/ml (Figure 4.4d). Although sera from normal controls and cancer-bearing
mice were differentiated at all four concentrations, we chose 5 mg/ml total serum proteins
for further experiments because of its stable and differentiable fluorescence responses.
Both sensors were able to classify all 8 clusters of 64 samples (4 concentrations × 2
serum types (normal and cancerous) × 8 replicates). PFS-PPE1 performed better than
PFS-PPE2 with 89.1 % versus 12.5 % (Figure 4.4c) in unknown identification and we
chose the PFS-PPE1 pair for all of our mouse serum experiments.
Serum protein levels vary from patient to patient even when they have the same
type of cancer, one challenge for cancer diagnostics.33 This motivates us to examine the
effect of individual differences from cancer-bearing mice of the same cancer model. We
prepared five normal healthy controls (M1 to M5) and five transgenic cancerous mice
(M6 to M10). The LDA plot shows distinct clusters for the control versus cancerous
groups, with all five healthy controls and all five cancerous mice clustering together
within their respective groups with 100 % accuracy (Figure 4.5a). To test the
reproducibility of our PFS-PPE1 sensor, we generated 80 blinded cases (5 mice × 2 types
(normal and cancerous) × 8 replicates) for unknown prediction (Figure 4.5b), results in
98.7 % of correct unknown identification of normal and cancerous samples from the
transgenic lung model (Figure 4.5c).
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Figure 4.5. Detection of mouse serum samples from the transgenic lung cancer model
using PFS-PPE1 complex. (a) LDA plot of the PFS-PPE1 complex responses to serum
samples of five normal and five cancerous mice. The analysis resulted in canonical scores
with two discriminants explaining 97.9 %, and 1.4 % of total variance and was plotted
with 95% confidence ellipses around the centroid of each group. (b) Unknown mouse
serum samples were clustered with the established reference serum via LDA using the
fluorescence responses. (c) Results of unknown identification of 80 mouse serum samples
using LDA algorithm.
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Figure 4.6. Detection of mouse serum samples from lung cancer model using PFS-PPE1
complex. (a) LDA plot of the PFS-PPE1 complex responses to serum samples of five
normal and five cancerous mice. The analysis resulted in canonical scores with two
discriminants explaining 95.8 %, and 3.6 % of total variance and was plotted with 95%
confidence ellipses around the centroid of each group. (b) Unknown mouse serum
samples were clustered with the established reference sera via LDA by using the
fluorescence responses, resulted in a 100 % CUI.

We tested the generality of the PFS-PPE1 sensor using another mouse model: a
lung tumor model induced by H1299-EGFP-luc2 cells. This model includes 10 mice (5
normal healthy mice and 5 cancerous mice) (Table 4.2). Similar to the transgenic cancer
model, the LDA plot of this model differentiates between normal and cancerous mice
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with 100 % classification accuracy (Figure 4.6).

Our assay also picks up the

heterogeneity in different cancerous mice within the same tumor model. In all the mouse
models, there are more variations among cancerous mouse samples than the normal
controls.

	
  

Figure 4.7. Combined serum data from both models: transgenic and experimental lung
models. (a) LDA plot of the PFS-PPE1 complex responses to combined cancerous serum
samples and combined normal serum samples. The analysis resulted in canonical scores
with two discriminants explaining 99.3 %, and 0.7 % of total variance and was plotted
with 95% confidence ellipses around the centroid of each group. (b) Unknown mouse
serum samples were clustered with the established reference sera via LDA by using the
fluorescence responses, resulted in a 87 % CUI.

78

The ultimate goal of a diagnostic test is to answer the question of whether or not
the patient has cancer. For this purpose, we combined all control samples from both
transgenic lung and experimental lung models to serve as the reference for normal
healthy mice, and cancerous samples from both models as the reference for cancerbearing mice. LDA analysis shows 91 % of classification accuracy between normal and
cancerous samples from both cancer models. Unknown prediction for this combinedmodel data set is also very effective, 87 % (Figure 4.7).

	
  

Figure 4.8. Receiver operating characteristic (ROC) analysis of the combined data from
both transgenic lung and experimental lung models. The accuracy of the test depends on
how well the test separates the group being tested into those with and without cancer. An
ideal diagnostic test would have the true-positive rate equals one and the false-positive
rate equals zero. AUC was calculated to be 0.95 with a sensitivity of 91.2 % and a
specificity of 85.0 % using the cut-off level at 0.27. Cut-off level is the optimal threshold
to maximize TPR while minimizing FPR.
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An important and useful technique for evaluating the performance of diagnostic
tests is the receiver operating characteristic (ROC) curve.34 Conventionally, the
performance of a diagnostic test is usually summarized by two quantities related to the
two types of errors: true-positive rate and false-positive rate. The true-positive rate is the
probability that a patient with cancer is correctly classified as having cancer, and the
false-positive rate is the probability that a patient without cancer is incorrectly classified
as having cancer. In other word, the true-positive rate reflects sensitivity and one minus
the false-positive rate reflects specificity. An ideal diagnostic test would have the truepositive rate equals one and the false-positive rate equals zero. For cancer screening, the
false-positive rate needs to be very low; otherwise, an inordinate number of screened
healthy subjects will have unnecessary harmful therapies.35 Figure 4.8 shows the ROC
analysis of the sensor when using the combined data from both transgenic lung and
experimental lung models in the unknown identification. The AUC was calculated to be
0.95 (95 % confidence level: 0.92-0.98) with a sensitivity of 91.2 % and a specificity of
85.0 % using the cut-off level at 0.27. The AUC value obtained in our study is well
within the excellent diagnostic accuracy range (AUC = 0.9-1.0).36 Our test is also well
above the standard accuracy range required for most diagnostic tests37 and is more
accurate compared to most tests using single specific biomarker.38-40

4.4. Conclusions
We demonstrated a robust FRET-based polymer assay, which rapidly
differentiated healthy controls and cancer-bearing mice using their sera. In total, 224
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cases from 20 mice were accurately and readily identified within only minutes. This
sensor benefits from the highly responsive conjugated fluorescent polymers as well as the
simplicity of minimal sensor elements (only two polymers). In addition, the stability and
scalability of this polymer-based sensor make it an attractive strategy for point-of-care
testing.27 More importantly, serum is an easy accessed biofluid, which allows a simple
diagnostic and prognostic approach that poses low level of inconvenience to patients.

4.5. Experimental section
4.5.1. FRET optimization. A series of concentrations of PPE1 and PPE2 were
mixed independently with a constant concentration of the donor PFS at 0.2 µg/ml in 96
well plate. All fluorescent spectra were recorded at room temperature using Molecular
Devices Spectramax M5 plate reader with an excitation wavelength of 356 nm. PPE1 and
PPE2 concentrations were varied between 0.04 to 2 µg/ml and 0.1 to 1.5 µg/ml,
respectively. For the calf serum incubation study, each condition of each polymer pair
was incubated with 10 µL of undiluted calf serum for 30 minutes. The optimized ratios of
PPE1/PFS and PPE2/PFS were 1.5 and 5, respectively. To enhance the fluorescence
intensity of PPE1 and PFS, we kept the same ratio for this pair but increased their
concentrations to 0.75 and 0.5 µg/ml, respectively.
4.5.2. Animal models. Mice were maintained on standard mouse chow, and
housed in a specific pathogen-free barrier facility with ethics approval from the
University of Calgary Animal Care Committee and in accordance with Canadian Council
on Animal Care guidelines. Use of the non-small cell lung cancer model harboring
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p53R172HΔg/+ and K-rasLA1/+ transgenes has been described earlier.41 Experimental
Xenograft lung cancer model using H1299-EGFP-luc2 cells was previously described.42
Following necropsy, organs were fixed in 10% formalin for an average of 24 to 48 hours.
Skeletal tissue was then selected and placed into 88% formic acid for decalcification for
an average of 4-6 hours. All tissue was then subject to routine processing (8 hour
protocol) where tissue is sequentially placed into formalin then a series of graded
alcohols (70% to 100%) followed by xylene and then paraffin wax infiltration. Tissues
were then paraffin-embedded prior to sectioning and hematoxylin and eosin (H&E)
staining.
4.5.3. Mouse serum preparation. Blood was collected from hearts of mice using
syringes and carefully transferred to 1.5 ml eppendorf tube. These blood-contained tubes
were kept at room temperature for 45-60 minutes to induce blood clotting. After that,
samples were centrifuged at 13,000 rpm for 15 min at 4° C. After centrifugation,
supernatant was carefully aliquot into new eppendorf tubes for long-term storage at - 80°
C. Sterile PBS (pH 7.4) was added to dilute each serum sample in the amount of 200 µL,
in order to minimize serum lost after filtration. Each diluted serum sample was filtered
using a sterile 4 mm diameter syringe filter purchased from Corning®, with 0.2µm pore
RC membrane. The total serum protein concentration was determined by bicinchoninic
acid assay (BCA) and normalized by diluting to the same concentration with PBS before
sensing.
4.5.4. Sensing studies. Appropriate concentration of each polymer was mixed
together in PBS (pH 7.4) based on previous optimizations. Each of the PFS-PPE
complexes was loaded (200 µL) into a black 96-well untreated plate (Costar), followed
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by the addition of 10 µL of 210 µg/ml protein solution in PBS or 5 mg/ml total serum
protein concentration of each mouse. The mixture was incubated for 30 minutes before
their fluorescence intensities were recorded at EX/EM (nm) of 356/420, 408/480,
356/480 for PFS-PPE1 pair, and 356/420, 418/482, 356/482 for PFS-PPE2 pair. The
fluorescence intensities of the sensor only (without any analyte) is I0, while the intensities
of the sensor with analytes after 30 minutes of incubation is I. Normalized fluorescence
of each sample is I/I0.
4.5.5. Receiver operating characteristic analysis (ROC). To evaluate how well
LDA predicts the unknown samples, we ran ROC analysis. We used lda function in
MASS package43 of R to train set 1 then use algorithm trained in set 1 to predict set 2. The
ROC curve is created by plotting the true positive rate (TPR) against the false positive
rate (FPR) at various threshold (cut-off level) settings using ROCR package. Cut-off level
is the optimal threshold to maximize TPR while minimizing FPR to achieve the most
effective diagnostic test. The accuracy of the test depends on how well the test separates
the group being tested into those with and without cancer. Accuracy is measured by the
area under the ROC curve, also known as AUC (the area under the curve). An area of 1
represents a perfect test; an area of .5 represents a less accurate test. AUC was obtained
by the auc function in pROC package. Sensitivity and specificity were weighted equally
in the prediction.
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CHAPTER 5
RAPID DETECTION OF ENDOCRINE DISRUPTING CHEMICALS BY A
NANOSENSOR AT ULTRA-SENSITIVE LEVEL

5.1. Abstract
Endocrine disrupting chemicals (EDCs) interact with estrogen receptors (ERs),
causing a range of adverse health effects. Current assays for EDC activity are slow and
often lack sensitivity.

We report here an ultra-sensitive nanosensor that can detect

estrogenic cellular changes in ER(+) MCF-7 cells rapidly (minutes) at levels orders of
magnitude lower than generally used assays. Notably, the sensor responses at these ultralow EDC levels correlate with an increased synthesis phase (S-phase) cell population of
EDC-treated cells. The nanosensor was also able to detect binary EDC mixture effects,
with synergism observed for bisphenol A (BPA) - 17β-Estradiol (E2) and antagonism for
Dicyclohexylphthalate (DCHP) - E2, and Benzo(a)pyrene (BaP) - E2.

5.2. Introduction
Endocrine disrupting chemicals (EDCs) are structurally diverse compounds that
interfere with the endocrine system, cause a broad range of adverse effects.1-4 EDCs
featuring estrogenic activity are of particular importance, posing a significant threat to
reproduction and developmental processes in human and wildlife,5 In common with other
toxicological threats, there are tens of thousands of chemicals in use whose estrogenic
effects are unknown.
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Proliferative assays that rely on increased cell reproduction upon exposure to
EDCs are by far the most widely used test for estrogenic activity. The widely used Escreen proliferative assay requires a six-day exposure period. The inability of this
protocol to detect low-dose effects in the pico-and femtomolar range causes many false
negatives.6-8 Recently, flow cytometry assay has been used to detect estrogenic responses
arising from lower EDC concentration exposures by detecting the percentage of cells in
the S-phase.6 This assay, however, requires substantial sample preparation and
specialized instrumentation, limiting its ability to address the high throughput demands of
environmental toxicology. Recently, engineered bacterial sensor was developed to screen
estrogenic EDCs at low concentrations. However, while this technique is quite rapid and
convenient, it does not measure the direct phenotypic changes after EDC exposures that
are relevant at a cellular level. Therefore, this design is more susceptible to false
positives.9
The wide range of health issues generated by EDCs suggests that there is likewise
a range of phenotypic consequences of EDC exposure at the cellular level. Predicting
these changes on the molecular level is, however, quite challenging.10,11 To address this
issue, we report here the use of a hypothesis-free nanosensor to detect estrogenic EDC
response of cells at pico- and femtomolar levels. This sensor system uses a gold
nanoparticle (AuNP) as a recognition element and green fluorescence protein (GFP) as a
transducer.12 This sensor platform can capture the overall chemicophysical changes of the
EDC-treated cells in minutes, avoiding false negatives due to the limitation of the typical
single endpoint readout of current assays.13 The simplicity of this method makes it
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likewise a practical tool for addressing the real-world challenge arising from mixtures of
EDCs.

5.3. Results and Discussion
We used a sensor system composed of non-covalent complexes of AuNPs and
GFPs. We chose the benzyl nanoparticle (BenzNP) due to its sensitivity to differences in
cell surfaces.14 The fluorescence of the GFP is quenched when bound to BenzNP, with
fluorescence restored upon displacement by cell surface functionality (Figure 5.1).15-17
Human breast cancer MCF-7 cells were used in our study. This cell line is widely
employed in EDC studies5,6,8 due to their high level sensitivity to estrogenic agents.18,19

	
  

Figure 5.1. Schematic illustration of the nanosensor. (a) The sensor consists of BenzNP
and green fluorescence proteins (GFPs). The fluorescence of GFP is quenched when the
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BenzNP–GFPs complexes are formed. (b) When nanosensor is added to cells with and
without EDC treatment, due to the different phenotypes of untreated and treated cells,
BenzNP interacts differently with the cell surface and releases different amount of GFP,
generating signal output.

Our initial experiments focused on establishing the response of our sensor to
E2 as a positive control. MCF-7 cells were plated in 96-well plate overnight before being
treated with E2, using 10,000 cells/well. After 24-hour treatment, cells were washed with
Phosphate Buffer Saline (PBS), followed by the addition of the nanosensor BenzNPGFP. The sensor detected significant cellular changes of E2-treated cells at femtomolar
concentration (5 × 10-15 M). In contrast, there was no proliferative effect observed using
Hoechst dye at even five orders of magnitude higher in E2 concentration. Significantly,
co-incubation of cells with E2 and the anti-estrogen ICI 182,780 generated a response
identical to that of control (untreated) cells, verifying that the sensor was responding to
estrogenic changes in cell phenotype (Figure 5.2a). Our nanosensor was able to detect
cellular changes induced by femtomolar concentration of E2, a four order of magnitude
more sensitive than the conventional E-screen assay.6,19
We next tested our system on bisphenol A (BPA), an EDC that has generated
considerable controversy.20,21 The cells were treated with BPA for 24 hours prior to
sensing. A significant increase in fluorescence signal from the sensor is observed at
picomolar range (5 × 10-11 M, Figure 5.2b), while no significant response from Hoechst
dye.

Two

other

reported

EDC

agents,

Dicyclohexylphthalate

(DCHP),

and

Benzo(a)pyrene (BaP), likewise showed a positive response (Figure 5.2c).5,6,22
Significantly, BaP was successfully detected by our nanosensor at the concentration of 1
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× 10-11 M, even though no significant proliferative effect was observed with this EDC
using a standard E-screen assay.6

	
  

Figure 5.2. Fluorescence response from nanosensor BenzNP-GFP and Hoechst 33342
with and without co-incubation of estrogen receptor inhibitor ICI 182,780 with (a) 17βEstradiol (E2) and (b) Bisphenol A (BPA). Fluorescence response of BenzNP-GFP
sensor is significantly increased in the absence of ER inhibitor ICI 182,780 in both E2
and BPA treated cells at 10-15 M and 10-11 M respectively. (c) Fluorescence response from
nanosensor BenzNP-GFP for all tested compounds: E2, BPA, Dicyclohexylphthalate
(DCHP) and Benzo(a)pyrene (BaP). Each data point is the mean value of four replicates
per treatment (n=4).
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In reality, when we are being exposed to EDCs, it is usually a mixture of
compounds and not a single agent. Therefore, it motivates us to investigate the low dose
effect of EDC mixtures, starting with the binary mixtures of each tested compound
described previously with a non-significant concentration of E2 at 1 fM. We used a subthreshold dosing of E2 with the purpose of making the effects of binary mixtures more
apparent by eliminating the potential affect of E2 alone in higher concentrations. Series
of BPA, DCHP and BaP concentrations were prepared with and without co-incubation of
1 fM E2 to treat the cells for 24 hours before the detection by the nanosensor. To allow
comparison across different compounds, equipotent concentrations (PC50) need to be
calculated. PC50 indicates the concentration of compound x that evokes 50% activity of
the positive control, E2. This approach is more suitable for comparison than EC50 due to
the fact that not all compounds reach a relative proliferation effect of 100%.5,23
Interestingly, BPA-E2 mixture shows a drastic increase in fluorescence signal compared
to just single agent BPA. The PC50 of BPA-E2 mixture is much lower than that of BPA
alone (4.77 × 10-14 M and 1.57 × 10-10 M, respectively). This reduction in PC50 makes the
mixture of BPA-E2 even as potent as compared to E2 alone. This result is consistent with
previously published work using the traditional E-screen method.24 Other tested binary
mixtures of DCHP-E2 and BaP-E2 show an opposite trend with BPA-E2 mixture. While
BPA-E2 mixture indicates a highly synergistic effect, DCHP-E2 and BaP-E2 show
antagonistic effects, where their PC50 values could not be determined (Figure 5.3). The
binary mixture of E2 and another phthalate derivative, butylbenzyl phthalate, was shown
to be antagonistic in previous work.24 However, to the best of our knowledge, the mixture
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behaviors of DCHP-E2 and BaP-E2 are not previously reported in the literatures and are
new findings enabled by our technology.

	
  

Figure 5.3. Fluorescence response from nanosensor BenzNP-GFP for binary mixture
effects of 1 fM 17β-Estradiol (E2) with (a) Bis-Phenol A, (b) Dicyclohexylphthalate, (c)
Benzo(a)pyrene. Each data point is the mean value of four replicates per treatment (n=4).
d) PC50 values for individual compounds and binary mixtures with 1 fM E2. PC50 value is
the concentration of compound x with 50% activity of the positive control (17β-Estradiol,
E2).

Our sensor can rapidly detect cellular responses from ultra-low levels of
estrogenic agents, raising the question of what phenotypic change was being detected.
Estrogenic EDCs trigger cells to proliferate, which should result in an elevated
population of S-phase cells. The S-phase cell population can be measured by flow
cytometry. This method has been previously described as flow cytometric E-screen assay,
and was validated using a range of estrogenic compounds.6 In our study, cells were
treated with different concentrations of E2 and BPA for 24 hours, then trypsinized and
washed with PBS. Ethanol was used to stabilize these cells at 4°C. After 2 hours, cells
were stained with Propidium Iodine/RNAse solution before running flow cytometry. As
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observed in sensor response of E2 and BPA-treated cells, higher concentrations of E2 and
BPA induced more S-phase cell population, which become significant at 2.5×10-14 M and
1×10-11 M, respectively (Figure 5.4a). We observed a similar trend in the increased Sphase population as seen with the nanosensor BenzNP-GFP response. This increase in Sphase is eliminated when cells were treated with the co-incubation of E2 or BPA with the
anti-estrogen ICI 182,780 (Figure 5.4b). The direct correlation between our sensing
studies and the cytometric data provides solid evidence that our sensor is responsive to
cell cycle changes.

	
  

Figure 5.4. (a) E2 and BPA effects on S-phase cell population of MCF-7 measured by
flow cytometry. The S-phase percentage of MCF-7 cells increases as the concentration of
E2 or BPA increases. (b) Co-incubation effect of E2 and BPA with ICI 182,780, an
estrogen receptor antagonist, on S-phase cell population. The proliferation effect of
MCF-7 cells when treated with E2 or BPA is inhibited in the presence of 10 nM of ICI
182,780. Each data point is the mean value of three replicates per treatment (n=3).
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5.4. Conclusions
We have demonstrated the usefulness of our simple nanosensor, BenzNP-GFP,
for detecting low dose effects of estrogenic EDCs. This technique is rapid, versatile and
only involves one step process of adding the nanosensor solution into the EDC-treated
cells. We have successfully detected the estrogenic activity of an endogenous (E2) and
other xenogenous agents (BPA, DCHP and BaP) on MCF-7 cells at ultra low
concentrations (femto and picomolar ranges). The ease of performing this cell-based
assay using BenzNP-GFP complex has made it possible to test the effects of EDCs at a
broader range of concentrations. Whereas, a sensitive flow cytometry method still limits
number of samples one can perform due to multistep processing procedure. Significantly,
this nanosensor can also be used to detect EDC mixture effect, eliminating the lengthy
processing time comes with infinite number of possible combinatorial EDC mixtures.
Studying the combination behaviors is a step forward to better reflect the effects of EDCs
in a more complex system, such as in vivo. Such complexity can be complicated by the
pre-existence of endogenous estrogen, which when mixed with other xenogenous
substances, might be drastically different compared to single agent itself as observed in
our study.

5.5. Experimental section
5.5.1. Nanosensor (BenzNP and GFP) fabrication. To determine the
appropriate ratio of BenzNP and GFP for the assay, different concentrations of BenzNP
were first titrated with 150 nM GFP to find out at which concentration of BenzNP, GFP
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intensity can be quenched. Final concentrations of 100 nM BenzNP and 150 nM GFP
were used for all assays. The appropriate ratio of BenzNP and GFP was mixed with 5mM
Phosphate buffer (5mM PB) for 30 minutes to form nanosensor complexes and quench
the fluorescence intensity of GFP. This mixture was then added to cell microplate for
estrogenic activity detection.
5.5.2. Cell culture. For routine cell culture, MCF-7 cells were maintained in
Dulbecco’s Minimum Essential Medium (DMEM) with phenol red as pH indicator,
supplemented with 10% Fetal Bovine Serum and 1% antibiotics. Cells were grown in a
humidified atmosphere containing 5% CO2 at 37 °C. For estrogenic activity experiments,
MCF-7 cells were cultured in low steroid conditions with charcoal dextran treated fetal
bovine serum (CDFBS) in order to minimize estrogenic activity of serum and arrest all
cells at G0/G1 phase. More specifically, cells were transferred to DMEM-F12 (phenol red
free due to its known estrogenic activity) media, supplemented with 5% CDFBS and 1%
antibiotics for 3 days. After that, cells were seeded on 96-well plate for experiments using
only 2.5% CDFBS DMEM-F12 media to avoid cell overgrown and enhance estrogenic
effect in a serum deprived environment.
5.5.3. Cell number titration. a series of cell number from 2,000 to 10,000 cells
were plated on 96-well plate overnight (Figure 5.5). BenzNP-GFP complex solution with
co-incubation of Hoechst 33342 was added to the 96-well plate after one time washing
with Phosphate Buffer Saline (PBS). Alamar Blue/cell media solution was prepared in
the ratio of 1/10. This mixture was incubated with cells for approximately 3 hours before
being read out at EX560/EM590.
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5.5.4. Cell-based assay for estrogenic activity detection. 10,000 cells were
seeded on 96-well plate in 2.5% CDFBS DMEM-F12 media overnight. A series of E2 or
BPA concentrations were prepared in 2.5% CBFBS DMEM-F12 media with 0.1% EtOH.
Cells were washed with PBS and treated with these concentrations for 24 hours. After
that, cells were washed one more time with PBS. Appropriate ratio of BenzNP-GFP
nanosensor was mixed with 10 µg/ml of Hoechst 33342 and added into 96-well plate for
15 minute incubation time. The GFP and Hoechst fluorescence were measured with
EX/EM wavelengths of 475/495 nm and 355/460 nm on a Molecular Devices
SpectraMax M3 microplate reader at 25 °C. Normalization of fluorescence intensity was
done by I/I0, where I is the final fluorescence intensity and I0 is the initial fluorescence
intensity of the sensor.
5.5.6. Flow cytometry and cell cycle analysis. Serum deprived cells were seeded
on 6-well plate at a density of 180,000cells/well in CDFBS DMEM-F12. Six
concentrations of E2 and six concentrations of BPA (three replicates each treatment)
were incubated with cells for 24 hours. The highest concentration of E2 (1×10-10 M) and
BPA (5×10-7 M) were mixed with 10 nM ER inhibitor (ICI 182,780) to co-incubate with
cells, also for 24 hours. Cells were washed with PBS once before being trypsinized and
transferred into 1.5 ml eppendorf tubes. 1000 µL of culturing media was added into each
tube to stop the trypsin activity. Samples were centrifuged at 3000 rpm for 5 minutes and
the supernatant was discarded. 150 µL of PBS was added into each tube to resuspend
cells into solution. 350 µL of EtOH was added to stabilize cells at 4°C for two hours.
Cells were then centrifuged again to discard the supernatant before staining with
PI/RNAse mixed with PBS at 1:1. Flow cytometric measurements for cell samples were
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performed using a LSRFortessa 3 Laser, HTS flow cytometer (BD Biosciences). The data
was then analyzed using FlowJo 7.6 using Watson Pragmatic model for cell cycle
analysis.

	
  

Figure 5.5. Response of different sensing systems (BenzNP-GFP sensor, Alamar Blue,
and Hoechst 33342) with different cell numbers from 2k to 10k MCF-7 cells. BenzNPGFP complex is more sensitive to cell numbers than Alamar Blue and Hoechst 33342.
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CHAPTER 6
SENSING BY SMELL: NANOPARTICLE-ENZYME SENSORS FOR RAPID
AND SENSITIVE DETECTION OF BACTERIA WITH OLFACTORY OUTPUT

6.1. Abstract
We present here a highly efficient sensor for bacteria that provides an olfactory
output, allowing detection without the use of instrumentation, and with a modality that
does not require visual identification. The sensor platform uses nanoparticles to
reversibly complex and inhibits lipase. These complexes are disrupted in the presence of
bacteria, restoring enzyme activity and generating scent from odorless pro-fragrance
substrate molecules.

This system provides rapid (15 min) sensing and very high

sensitivity (102 cfu/mL) detection of bacteria using the human sense of smell as an
output.

6.2. Introduction
The human olfactory system has evolved to detect extremely low concentrations
of volatile organic compounds present in complex environments.1

Humans can

discriminate more than 1 trillion olfactory stimuli, several orders of magnitude greater
than their capability in visual discrimination.2 This sensitivity and versatility makes
olfaction a promising platform for biotechnological applications,3 however there have
been few examples of the application of translation of sensor responses to olfactory
outputs. 4-7
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Figure 6.1. Schematic representation of sensor elements used in this study. Cationic
AuNPs bind with the anionic enzyme inhibiting the catalysis of the pro-fragrance into
scent. Bacteria present in solution compete for the AuNP surface and displace the
enzyme inducing the production of the rose fragrance.

Nanotechnology provides new opportunities to redefine the bounds of human
perception.8 There have been a wide variety of examples where the intrinsic properties of
nanomaterials have been used to generate visual output,9,10 with additional examples of
nanomaterials modulating other colorimetric processes.11-13 Engineered nanomaterials
have also been shown to influence the behavior of fragrance molecules.14 In a recent
study, Weder et al. demonstrated cellulose nanocrystals functionalized with pro-fragrance
molecules that could be used to control the production of volatile compounds.4 These
covalently bound complexes remain odorless until functional groups are cleaved in
response to specific external stimuli, generating pungent aroma molecules.5 Taken
together, we hypothesized that pro-fragrances in combination with surface-engineered
nanomaterials could provide reactive constructs to transduce molecular interactions into
outputs that could be ‘read out’ through our sense of smell, providing a useful sensor
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modality for detection of bacteria that provides a potential strategy for combatting the
threat of bacterial drinking water contamination that contributes to over 1.5 million
deaths worldwide a year.15,16
We use a supramolecular-based approach to generate an effective smell-based
sensor platform for bacteria. The system is comprised of three tunable components: 1)
surface functionalized gold nanoparticles (AuNP), 2) pro-fragrance molecules, and 3)
enzymes to cleave the pro-fragrances to generate the olfactory output (Figure 6.1). In this
sensor, the surface moieties of the nanoparticles behave as both selective recognition
elements for analytes present in solution and to reversibly inhibit the complexed
enzymes.13 The pro-fragrance molecules17 provide a ‘turn-on’ response for the sensor
system, going from odorless to strongly odiferous upon cleavage by the enzyme. Finally,
the enzyme provides a strategy for amplifying the output, generating multiple fragrance
molecules per recognition event.18 Bringing these components together provides a
sensitive sensor system for bacteria, allowing human subjects to rapidly detect bacteria in
solution at levels as low as 102 cfu/mL, a relevant limit of detection for overall bacterial
load in drinking water, and consistent with other recently published sensor systems.19-22

6.3. Results and Discussion
Our sensor design uses nanoparticles to both recognize the bacteria and to inhibit
the fragrance-generating enzyme. We chose AuNPs possessing ligands with terminal
benzyl headgroups, as these nanoparticles have been shown to interact strongly with the
anionic cell surface of bacteria.

23,24

We used the robust and industrially used Candida

Rugosa lipase as the enzymatic amplifier, 25 relying on the negative charge of the protein
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to provide electrostatic complementarity with the cationic nanoparticle, and hence
inhibiting catalysis.11,26,27 Given the ability of human olfaction to discern an enormous
variety of scents, we had a wide range of pro-fragrance options to choose from. We
ultimately chose the succinic acid ester of phenylethyl alcohol (SAEPE) as our
substrate/pro-fragrance, due to the low odor threshold of phenylethyl alcohol,28 coupled
with the orthogonality of the pleasant rose scent with odors commonly found in
contaminated drinking water.

	
  

Figure 6.2. Lipase inhibition assay in the presence of benzyl AuNP. Lipase (15 nM) was
incubated with a series of benzyl AuNP concentrations before adding the colorimetric
substrate p-NPB (0.6 mM).
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We initially performed a colorimetric assay to optimize the AuNP:lipase ratio
required for inhibition.

These studies were performed using p-nitrophenylbutyrate

(pNPB) in sodium phosphate buffer solution (5 mM, pH 7.4). As shown in Figure 6.2, an
approximately 3:1 AuNP to lipase ratio provided essentially complete inhibition of the
lipase. This AuNP:lipase ratio was used to generate the nanozyme complex for all
further studies. This colorimetric assay was able to detect both Gram positive and
negative bacteria, including: E. coli, B. subtilis, M. luteus, and P. aeruginosa (Figure
6.3), indicating the generality of the enzyme activation process.

	
  

Figure 6.3 Detection of bacteria using the nanozyme complex with colorimetric substrate
p-nitrophenylbutyrate (pNPB) in sodium phosphate buffer solution (5 mM, pH 7.4). I0 is
the initial absorbance of the nanozyme complex without bacteria and I is the final
absorbance of the nanozyme complex in the presence of bacteria after 30 minutes of
incubation. E. coli, B. sub, M. luteus, P. aeru.
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We next turned to bacterial sensing using the enzyme platform, beginning with an
instrument-based analytical strategy. These studies used E. coli as a non-pathogenic
“safe” bacteria strain to minimize health concerns in both the instrumental and human
studies.29 Solutions of the sensor elements were incubated for 30 minutes prior to the
addition of the pro-fragrance. We then used headspace gas chromatography to quantify
the production of scent generated by our bacterial sensor.30 The concentration of the
volatile product present in the headspace of the sample vial was quantified according to
an external calibration curve (see Supporting Information). As shown in Figure 6.4, the
uninhibited lipase cleaves significantly more pro-fragrance than the nanoparticle-enzyme
complex and controls. Significantly, no signal was observed using the substrate alone and
bacteria, indicating that the bacteria do not hydrolyze the pro-fragrance in the timeframe
studied. As expected, the sensor system generated measurable and distinctly different
signals in the presence of 104 and 106 cfu/mL of E. coli.
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Figure 6.4. Headspace gas chromatography analysis of sensor response to increasing
concentrations of bacteria. Samples were prepared in triplicate. Error bars represent
standard deviations of the measurements. *= p< 0.05, ***=p<0.001.

Having established the generation of fragrance output, we next determined the
ability of humans to serve as “detectors”. Ten volunteers were asked to smell glass vials
at two time points: 1 minute as a control, and 15 minutes for sensing, with the interval
chosen to ensure olfactory clearance.31 They ranked the samples in order from least/no
smell (1) to strongest smell (5), and the raw ranking order data were analyzed using the
Kruskal-Wallace H-test. Initial studies focused on the sensitivity of the scent response.
As expected, participants were able to detect the phenylethyl alcohol at both time points
(Figure 6.5a). In contrast, the enzyme-substrate pair was not detected at 1 minute, but
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readily discerned at 15 minutes. In our sensing studies, no significant difference in
response was observed across conditions at 1 minute under any conditions; however after
15 minutes participants were successfully able to detect E. coli concentrations at both 102
and 104 cfu/mL (Figure 6.5b) with high significance relative to the controls. Interestingly,
102 cfu/mL of E. coli did not produce a detectable signal using gas chromatography,
demonstrating that human olfaction was more sensitive than the chromatographic
method.

	
  

Figure 6.5. Human olfactory detection studies. (a) Lipase activity test in the presence of
the pro-fragrance SAEPE was carried out with six participants. SAEPE only and 5 mM
Phosphate buffer were used as the negative control. The hydrolyzed form of SAEPE was
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used as the positive control (strong standard). Hydrolyzed SAEPE and SAEPE in the
presence of uninhibited lipase are significantly different from the negative controls
SAEPE alone (p<0.01 and p<0.01, respectively) after 15 minutes. (b) With ten
participants, olfactory detection of E. coli at 102 and 104 cfu/mL were compared to the
controls of just buffer and sensor only after 15 minutes. The olfactory signals from the
vials which contained 102 and 104 cfu/mL of E. coli are significantly different from the
signal from the sensor-only vial (p<0.001 and p<0.0001, respectively).

6.4. Conclusions
In summary, we report here the development of a supramolecular-based sensor
that uses the human olfactory system to read out the response. This sensor was able to
detect bacteria with high sensitivity. These studies demonstrate that by controlling the
behavior of responsive nanomaterials at the molecular level, we can alter how human
beings observe their surroundings in a manner that is otherwise impossible. We believe
this responsive strategy can be broadly applied to other surface functionalized
nanoparticles and enzymes to provide sensing of a wide variety of analytes, with the
availability of an almost limitless number of aroma profiles providing versatility
unavailable with other transduction strategies.

6.5. Experimental section
6.5.1. Bacteria Growth Conditions. Bacteria were cultured in LB medium at 37
°C and 275 rpm until stationary phase.

The cultures were then harvested by

centrifugation and washed with 0.85 % sodium chloride solution for three times.
Concentrations of resuspended bacterial solution were determined by optical density
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measured at 600 nm. 5 mM sodium phosphate buffer was used to make dilutions of
bacterial solutions.
6.5.2. Plate Reader Assay. Lipase inhibition assay was done at 25 °C with the
final concentrations in Costar clear 96 well plate of 15 nM lipase, 0.6 mM pNPB, and 20,
40, 60, 80, 100 nM benzyl AuNP. Lipase and benzyl AuNP were first incubated for 30
minutes in 96 well plate to insure their interaction reaches equilibrium, then 10 µL of
substrate p-NPB was added into the well. The activity of lipase was monitored every 30
seconds for a total of 40 minutes time frame at the absorbance of 405 nm.
6.5.3. Human Trial Assays.
Olfactory detection of lipase activity: Four different solutions were made in 20
mL glass vials with a final volume of 1 mL each. The volume of 1 mL was chosen to
maintain the easy-to-use format of the sensor for eventual on-site detection use. 5 mM
sodium phosphate buffer and 4 mM SAEPE were used as the negative controls and the
rose scent (2-Phenylethyl alcohol) was used as the positive control, a strong standard.
The activity of lipase was assessed by incubating 100 nM of lipase with 4 mM of SAEPE
for 20 minutes. The participants were asked to smell these samples and rank them in the
order from 1 to 5 with 1 has the lightest smell and 5 has the strongest smell.
Olfactory detection to determine the threshold of phenylethyl alcohol: Serial
dilutions of phenylethyl alcohol were prepared and detected by five volunteers to
establish the threshold of the rose fragrance. ‘Yes’ indicates that the volunteer was able to
smell the fragrance and ‘No’ indicates that no fragrance was detected. The threshold of
phenylethyl alcohol detected by volunteers was determined to be in µM range, which is
consistent with previous report (Table 6.1).28
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Table 6.1. Serial dilutions of phenylethyl alcohol detected by five volunteers.
Vial
#
1
2
3
4
5
6
7
8
9

Type
Fragrance
Fragrance
Fragrance
Fragrance
Fragrance
Fragrance
Fragrance
Buffer
Buffer

Conc.
(M)
0.05
0.01
0.005
0.001
0.0005
0.0001
0.00005
0
0

1

2

3

4

5

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No

Percentage
(%)
100
100
100
100
100
100
100
100
100

Olfactory detection of E. coli: The same procedure was followed as above for
buffer and sensor samples. For the E. coli-containing vials, 100 nM lipase was incubated
with 300 nM benzyl AuNP for 30 minutes, and then 10 µL of E. coli was added into each
vial so that the final concentrations of E. coli in each vial are 102 and 104 cfu/mL.
6.5.4. Gas Chromatography Head-Space Analysis. Headspace phenylethyl
alcohol was measured using a gas chromatography (model GC-17A, Shimadzu Co.,
Tokyo, Japan) equipped with a solid-phase microextraction (SPME) auto injector (model
AOC-5000, Shimadzu Co., Tokyo, Japan). Samples (1 mL) in 20 mL glass vials capped
with aluminum caps with polytetrafluoroethylene (PTFE)/silicone septa. Samples were
prepared using 500 nM lipase, 1.5 µM benzyl AuNP, and 4 mM of SAEPE. A 50/3 µm
divinylbenzene (DVB)/carboxen/polydimethylsiloxane (PDMS) stable flex (SPME) fiber
(Supelco Co., Bellefonte, PA) was then inserted into the vial headspace for 2 min to
absorb volatiles. The fiber was transferred to the GC injector port (250 °C) for 3 min.
The injection port was operated in split mode, and the split ratio was set at 20:1.
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Volatiles were separated on a fused-silica capillary Equity-1 Supelco column (30 × 0.25
mm inner diameter × 25 µm) coated with 100% PDMS at an initial oven temperature of
70 °C to final temperature of 220 °C over 10 min (step rate 15 °C/min). A flame
ionization detector was used at a temperature of 250 °C.

Phenylethyl alcohol

concentrations were determined from peak areas using a standard curve made from
dilutions of phenylethyl alcohol in 5 mM sodium phosphate buffer. Each measurement
was performed in triplicate and results were expressed as mean values ± standard
deviation.
6.5.5. Kruskal-Wallace H-test. Kruskal-Wallis test is a non-parametric version
of one-way ANOVA which is applied when the assumption of normal (Gaussian)
distribution is not met. This test can compare the medians of multiple samples to
determine if they come from the same population or not. This methodology uses ranks of
the data to compare the test statistics. To do so, the results from all groups are pooled and
arranged in rank order from smallest to largest. The numeric index of this ordering is then
used to evaluate the null hypothesis (sample are coming from the same distribution) using
chi-square statistics. MATLAB software (MATLAB and Statistics Toolbox Release
2012b, The MathWorks, Inc., Natick, Massachusetts, United States) was used to perform
Kruskal-Wallis test.32,33
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CHAPTER 7
FUTURE TRENDS IN CHEMICAL-NOSE SENSING
	
  

Chemical-nose sensors have been proven to be an effective approach for complex
mixture identification. This method truly shines when the knowledge of the biomarker in
the mixture of interest is poorly characterized.
For cancer diagnostic applications, chemical-nose sensors hold great promise to
be transformed into useful point-of-care tests (PoC) due to their simplistic design and
rapid detection capability. These features are desired for the development of PoC tests to
meet the ASSURED guidelines established by the World Health Organization. PoC tests
using chemical-nose approach are even more valuable in settings that have limited access
to clinical facilities such as suburband areas, especially in developing countries.
For environmental toxicity testing, chemical-nose sensors are the “first line of
defense” as it can act as a primary screening tool to identify which compound or mixture
can potentially pose a threat to humans and the environment. Using this approach,
~72,000 uncatagorized compounds can be rapidly screened and narrowed down to the
most harmful compounds, without the costly and time-consuming process such as the
screening program assays established by the Environmental Protection Agency (EPA).
Further testing is required to gain detailed insights about the mechanisms of action for
these compounds or mixtures. In addition, many compounds are only toxic after being
metabolized. Therefore, testing only the parent molecules can yield false negative results.
To cover the wide range of toxicity, in-vivo tests are desirable. However, to reduce the
cost, other in-vitro tests that can capture the metabolisms of compounds of interest are
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more suitable for primary screening. These tests could potentially utilize liver cells or
organ-on-the-chip technology to screen the metabolites of the parent compounds.
Chemical-nose sensor demonstrated its usefulness in the bacterial detection
application, where a general ‘yes’ or ‘no’ answer to the bacterial existence in drinking
water is typically sufficient for in-the-field testing. However, if we want to extend the use
of the chemical-nose sensing approach to other specific settings in bacterial detection
such as food quality control, restaurants, and hospitals, more vigorous sensing tests need
to be developed. These ‘nose’ tests should be more specific toward mixtures of bacteria
in general, and not respond to any other analytes such as other food ingredients or
sanitizing agents. For this purpose, ‘nose’ sensors are required to establish a base line
describing the common background found in those specific settings. This is a requirement
that is not essential for bacterial detection in drinking water due to its relatively simple
environment (not many compounds or organisms exist in drinking water).
Chemical-nose sensors offer a new pathway for point-of-care testing thanks to
their simplistic design and relatively low-cost materials. However, to successfully
implement this sensing approach for PoC testing, much more effort needs to be
contributed in this field to increase the sample size and extend the analyte map. This will
lead to big data trends in chemical-nose sensing, which requires more data scientists to
validate ‘nose’ tests using appropriate statistical analysis, including machine learning
approaches, something with which not all biologists and chemists are comfortable
handling. Taken together, the success of ‘nose’ sensor in the PoC testing field will require
the convergence of interdisciplinary knowledge in biology, chemistry and statistics.
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Advances in pattern recognition sensing will then be truly transformative, making rapid
and highly personalized diagnosis a reality.
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